Official source · cited records
PubMed
2,673 public records from PubMed that PeptideScanner profiles or records cite, newest check first. Inclusion is not a source rating, endorsement, or claim of comprehensive monitoring.
Page 1 of 6
Official source · 2,673 cited records
- Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques. · retained source version 1:2026-11-17:current:435b8b15458aa919dd3758a413e19032c9f76b6b2bc81b65f4d46e0debb20935 ↗Source checked November 17, 2026
- Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure. · retained source version 1:2026-11-14:current:6a0f889ab8890d1cbbef3a1aab9a889de06ca252cacd6c267bdb3ab7abb6c7cf ↗Source checked November 17, 2026
- [Antiviral activity of immunomodulator Selank in experimental influenza infection]. · retained source version 1:2018-12-17:current:ecd4c61458451cf7662a10903283bc799744e0836821828adb68ea8a9bc8979f ↗Source checked November 16, 2026
- [Boosting oxytocin in postpartum depression]. · retained source version 1:2026-08-12:current:8221c7cc1c8a153f27a2f71777a1f9d19cf15764e8444ead080e02cdc382cfd8 ↗Source checked November 16, 2026
- [Capillary isotachophoresis--a new method in drug analysis. 1. Analytic capillary isotachophoresis of the peptide drugs saralasin, gonadorelin and protirelin]. · retained source version 1:2014-11-20:current:6c4be2d2cc33e35366465e279b8c9db6e57f56d66bbcb12f3ae6746926688c8c ↗Source checked November 16, 2026
- [Cerebrolysin for acute ischemic stroke]. · retained source version 1:2026-04-27:current:68fa0f84cf2b1adbf1eaa3d4adf6402aa09310934393d8b15c5d46bc382c7e33 ↗Source checked November 16, 2026
- [Cerebrolysin in the treatment of brain injuries of moderate severity]. · retained source version 1:2016-11-25:current:1a525ebdb1e01eb01908320f450982557ef7d47e1dac4099806867731f5aad1b ↗Source checked November 16, 2026
- [Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial]. · retained source version 1:2025-07-03:current:d4263115695b0cc84694d2895811ceace8f81d4604314885edfe3a0bdb3cb90e ↗Source checked November 16, 2026
- [Comparative clinico-therapeutic study of gonadorelin and chorionic gonadotropin in boys with undescended testes]. · retained source version 1:2009-11-11:current:98d0b939a25c6347cc32cc6f2d8512df2a52c9224569ae351aa8f892c458d9ae ↗Source checked November 16, 2026
- [Efficiency of cerebrolysin in the diabetic polyneuropathy in patients with insulin-dependency diabetes mellitus]. · retained source version 1:2016-11-25:current:a855be36348ebfc936946c0babd0e6fa98626aff6c511465b83843e50b8ff716 ↗Source checked November 16, 2026
- [Enfuvirtide: first drug of a new family of antiretroviral agents]. · retained source version 1:2019-11-09:current:092f9a5ab7ec13cb95f46908c1ee994d79414fcc73845f6d5ea7f3206224c24b ↗Source checked November 16, 2026
- [Evaluation of the use of thymopentin in patients with progressive systemic sclerosis]. · retained source version 1:2013-11-21:current:6327bcf4d22ec29b0e05078f7fc7b1f9725b7720fc9868cd99e36abbf74f4c0e ↗Source checked November 16, 2026
- [Experimental optimization of learning and memory processes by selank]. · retained source version 1:2018-12-17:current:149691f15004bb6ceb48792cb6bbbe66b4ac775a2d53a2e73cebdd61683e5c91 ↗Source checked November 16, 2026
- [Expression of mechano-growth factor and its roles in tissue repairs and regeneration]. · retained source version 1:2012-06-18:current:4fbaa8a31d05195407221d7c25de9f0de5a57a34f107a6ab70c285e22145427a ↗Source checked November 16, 2026
- [Expression of mechano-growth factor in Escherichia coli and activity analysis]. · retained source version 1:2020-12-09:current:5dcd4db4361b7e0d38e6b610f71f39917470063022ad787f0475efa461cf7c5a ↗Source checked November 16, 2026
- [Hormonal treatment of undescended testicles with gonadorelin (LH-RH)]. · retained source version 1:2006-11-15:current:511e2bde5f543723b6b53648cfdf330ca8fb4da33371391a7546ed818ee9d6f5 ↗Source checked November 16, 2026
- [Humanin: a mitochondria-hidden peptide serving inflammation resolution]. · retained source version 1:2026-04-24:current:0bece47cb6b5d2543d890e5086a880b8b814b088fcf32073eac7b4eaba7d3113 ↗Source checked November 16, 2026
- [IGF-1 alternative splice isoforms: mechano growth factor]. · retained source version 1:2013-11-21:current:a8292f6aa89f6226860db9a01142ae3f35f30f84c520ded22776310c9a694a3c ↗Source checked November 16, 2026
- [Larazotide as an option in case of failure of a gluten-free diet]. · retained source version 1:2021-08-27:current:1b51f8c755ae38112bf43dd63cf537268b80e3354f1473c66a7484d524a6e5da ↗Source checked November 16, 2026
- [Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis]. · retained source version 1:2017-03-03:current:bc60174a294c1639ef907d469458631287e593210d382f3c1d1910a774a5b2db ↗Source checked November 16, 2026
- [Nesiritide in heart failure: commercial success or therapeutic advance?]. · retained source version 1:2007-11-15:current:50d49c15ce3e93d74ad767e32fd3563f49a500d28d282431b92ec779b3b8f088 ↗Source checked November 16, 2026
- [Optimization of the treatment of anxiety disorders with selank]. · retained source version 1:2018-12-17:current:2793cb613a2d9e10156bc8a73c0208493564e1a5e0dad329570d64a7cb77f68d ↗Source checked November 16, 2026
- [Peridural analgesia with dexamethasone and thymopentin: influence of the hypothalamo-hypophyseal axis]. · retained source version 1:2013-11-21:current:9b70d5566097d1e4161fb1ca2a12b1ed4a78d0665001a2c6068ad3b5163ea673 ↗Source checked November 16, 2026
- [Post-traumatic panhypopituitarism. Contribution of the gonadorelin pump to the topographic diagnosis]. · retained source version 1:2016-12-09:current:db700867af282ece576b260fc5dd51c95e15a3d497ac30b7420c7cf9b02c8655 ↗Source checked November 16, 2026
- [Recurrent urinary tract infections. Biological suppositions and clinical treatment with thymopentin]. · retained source version 1:2017-01-26:current:02bff1df23ba6f6a253f5b4b3fb55523fbcadf61fb1fbc148ec4ff0ef2ec8679 ↗Source checked November 16, 2026
- [Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients]. · retained source version 1:2007-11-15:current:1a6eeca5e5a62e99a3da46249fe506f6f3b424381cd8bc29a1270d7d5e569657 ↗Source checked November 16, 2026
- [Salmon calcitonin in the treatment of osteoporosis]. · retained source version 1:2016-11-24:current:c34ce0666cbf3fab489b8ff36c22a11b556302833760b8ed41d29e2964787263 ↗Source checked November 16, 2026
- [Secretin]. · retained source version 1:2015-11-19:current:b56c77cb7140992ae426fb109e4c95a95ee184cfa80ec36c73aa641589e3035e ↗Source checked November 16, 2026
- [Some possibilities for application of "Pfizer" medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice]. · retained source version 1:2018-12-01:current:fdd1cd3fe6b4eba2d5b876d8120c34bfc10a0853dd1c8ab4b2c5b5ebd3726978 ↗Source checked November 16, 2026
- [Spanish recommendations for proper use of enfuvirtide]. · retained source version 1:2026-01-28:current:25dd5606a2d6f79d9463cbde9a4a83498bb3a2ebc010da91dbc95bb2830a33d2 ↗Source checked November 16, 2026
- [Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis]. · retained source version 1:2016-11-23:current:b92a39df035eb3be6002b647127265038fff3dd523d79e8c814ddd2d41f60524 ↗Source checked November 16, 2026
- [The influence of salmon calcitonin on the soluble form of VCAM-1 (CD 106) and E-selectin (CD 62E) in serum of patients with atopic bronchial asthma]. · retained source version 1:2017-03-06:current:a00b82be74c45ebe20622b19cb50c4e1de403f2b9ed2bcf1523da50cbd649381 ↗Source checked November 16, 2026
- [The use of Synarel (nafarelin acetate--spray) in gynecology]. · retained source version 1:2017-11-16:current:888553936195769cde16bc38fe25ae96fbdcdceee2338ffcf2f86b0e3d0c9811 ↗Source checked November 16, 2026
- [Therapeutic indications, antiretroviral treatment optimization and quality of life of patients taking enfuvirtide]. · retained source version 1:2018-12-01:current:5cf6b256b5440c1b05b884638cf2ca11afcd56a418ed7ab1623d9cbd8a6499ed ↗Source checked November 16, 2026
- [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank]. · retained source version 1:2019-11-12:current:5d915deff760128abda3848a090dc64dd9266b0948745a1acbedc5eff2e9ae63 ↗Source checked November 16, 2026
- [Translated article] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections. · retained source version 1:2026-05-18:current:9762e03be0f30d612f408f534042a28adf3b9ec08b59ce827cd6bb2a6a644885 ↗Source checked November 16, 2026
- [Treatment of nocturia in men with desmopressin]. · retained source version 1:2019-07-24:current:4f4f6b7946e551f72effbecc8da5e7ddbb18bce19167604393e64eab9ddaf86f ↗Source checked November 16, 2026
- [Treatment of primary osteoporosis with calcium and salmon calcitonin]. · retained source version 1:2016-11-23:current:f0c82863461bfbe12b583b377b52251011c0a3fa7b1e80c24c26c12c96d96da7 ↗Source checked November 16, 2026
- 177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor. · retained source version 1:2026-11-09:current:2c5a2129914322b9eebe77cbd801ca14e4d2a98fc31cf4c20998d6eaa3b07c54 ↗Source checked November 16, 2026
- A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection. · retained source version 1:2024-10-30:current:241b7d23cf528c17a5001110748a18b2737cf5fd5c56132f013aca51316f1e7f ↗Source checked November 16, 2026
- A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. · retained source version 1:2019-08-28:current:b3fcb2395c5d11a581c659d2dc59b6fa3163175df0456d3e6037790d1e69aad1 ↗Source checked November 16, 2026
- A comparison of nafarelin acetate and danazol in the treatment of endometriosis. · retained source version 1:2019-07-07:current:8a7463dc7627eb98ba32e4ac169d6dec895010907a520aafc5291ef05277e27b ↗Source checked November 16, 2026
- A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke. · retained source version 1:2026-08-05:current:2edcf050324ea825bde55c9b61265676e26fae450a97efd6140f454851e56fd8 ↗Source checked November 16, 2026
- A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. · retained source version 1:2019-11-02:current:7f31f79e7aa9eaefa20ddc7790b9211dfe20c60d3328ed01caec0f6c5a16a88b ↗Source checked November 16, 2026
- A narrative review on oxytocin at the intersection of sleep, stress, and social behavior. · retained source version 1:2026-11-05:current:1425831914fec2bf869c48492059500e986d08d29fb88b5f1209556a548370d3 ↗Source checked November 16, 2026
- A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. · retained source version 1:2023-10-29:current:7abcb6a38061fd1b97907c94a94e6fc015836370c92816ed80a5e26b9c2c02b2 ↗Source checked November 16, 2026
- A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor. · retained source version 1:2009-11-19:current:37302e8b84a8822a0c842a35f5af7233ebd9fdeef8bda551f9c8eb9804646fc5 ↗Source checked November 16, 2026
- A new property of the synthetic anxiolytic Selank and its derivatives. · retained source version 1:2026-10-16:current:5b634629ab1b75498b62da82dbe300d9b98ce6b2c7c2ce739afc75d03bde1a61 ↗Source checked November 16, 2026
- A new synthetic porcine secretin for facilitation of cannulation of the dorsal pancreatic duct at ERCP in patients with pancreas divisum: a multicenter, randomized, double-blind comparative study. · retained source version 1:2017-01-09:current:3d957e7ef22431bddd753df06e17d5f280fb4928b24a2f467664ff596daa2934 ↗Source checked November 16, 2026
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. · retained source version 1:2020-09-28:current:119290be0a9227da4e13a6d6e7b17e6b9c7f0db5a220dcd0b910f78571665d5c ↗Source checked November 16, 2026
- A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. · retained source version 1:2026-11-09:current:661fc7a368b93a94cbf38f0f500a456e1c3435412041e6d46715a17783bed724 ↗Source checked November 16, 2026
- A prospective study of thymopentin in severely burned patients. · retained source version 1:2013-11-21:current:b0a8008d11e6e5db5e22404e1b3cdb4f1a668c84dc4890124b39a901e59b2db2 ↗Source checked November 16, 2026
- A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH). · retained source version 1:2026-01-27:current:ba58628c0beef757f4e4825a52f77867ffc52d264d030e3ed88a2aca67ecfdc0 ↗Source checked November 16, 2026
- A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. · retained source version 1:2021-10-20:current:6ca15a4007650983c8047cd3e6ad8747d419aabb38f444f738d9d60bce71acc4 ↗Source checked November 16, 2026
- A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. · retained source version 1:2018-12-01:current:58346b565f25c6741cc00fd2a130aa8c2dcb3c3f956750d9672c99e3d1e7a7bd ↗Source checked November 16, 2026
- A review of the use of histrelin acetate in the treatment of prostate cancer. · retained source version 1:2012-11-15:current:9f9e6f88d18fd227a203ad6f25e1e86f28402d4d36e82140e01970f777c543f2 ↗Source checked November 16, 2026
- A single growth hormone (GH) determination is sufficient for the diagnosis of GH-deficiency in adult patients using the growth hormone releasing hormone plus growth hormone releasing peptide-6 test. · retained source version 1:2019-12-10:current:7615c4a28d67f418798598147cd486424ac7332a8bbaa59dcb53125b8466197a ↗Source checked November 16, 2026
- A systematic review of secretin for children with autism spectrum disorders. · retained source version 1:2025-06-26:current:0b0736c88babb1641dae2ff7f5228bb4040f2115c8c9edf66cfb58eac92dced4 ↗Source checked November 16, 2026
- A thymosin beta-4 is involved in production of hemocytes and immune defense of Hong Kong oyster, Crassostrea hongkongensis. · retained source version 1:2026-01-27:current:85833121afa45556e9b3ee3b308df3c3dd8f19e9789516bf9f9fd66af7898286 ↗Source checked November 16, 2026
- Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa. · retained source version 1:2019-08-13:current:1c8d1fe5f16fc74e7fc186215bdaa319d71306fbbe872b08fdaa295b00cdd863 ↗Source checked November 16, 2026
- Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. · retained source version 1:2019-05-10:current:5e9cef868ebbcb1e59cd06b650f0b86a4fe10898e4aa56ea5faad38d595e7796 ↗Source checked November 16, 2026
- Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. · retained source version 1:2020-04-27:current:0bdf624c6ce7456976697ee6c4830fe2a0598a9849f4d2bdb8f15a3fad481611 ↗Source checked November 16, 2026
- Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. · retained source version 1:2018-12-01:current:4d52bea60655cb92ea0aab368e3f255cbaebc153010f94b2eccb94412f45e39f ↗Source checked November 16, 2026
- Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration. · retained source version 1:2023-12-16:current:6cbae629cab39e9a8ad202208d61b873c50c2f47f50edb4b993131d55ea37dc7 ↗Source checked November 16, 2026
- Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin. · retained source version 1:2023-03-31:current:b7c860f5c58dad4d9afb58fd3b30d6d55fc5ecbe7c9ec2938d443ed83b157178 ↗Source checked November 16, 2026
- Albiglutide (Tanzeum) for Diabetes Mellitus. · retained source version 1:2018-11-15:current:b70b136a9626db697b26f0f695d4ab1e21b22ffb4d2fa91a83152b606bbb958a ↗Source checked November 16, 2026
- Albiglutide for the treatment of type 2 diabetes mellitus. · retained source version 1:2019-07-18:current:ca7d24f9bad8bbc367e96cbe7a86a071c19cd79aa46b8581d99c06afa7963a84 ↗Source checked November 16, 2026
- Allergic reaction to mecasermin. · retained source version 1:2009-08-11:current:2b30cd4ab6230a7e3343ce9bfab1d8cd889ceff88b49ca2ac4cba08ba2ffcc2e ↗Source checked November 16, 2026
- Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment. · retained source version 1:2026-01-27:current:7ec76267203350b36928e36b618105498b1c230a81c7272d094bd1e53d4dcac2 ↗Source checked November 16, 2026
- An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin. · retained source version 1:2026-11-09:current:1f5c14788450c482de6ce4963578e476b0091cb71aa0ba6c54bf5152d5aeee41 ↗Source checked November 16, 2026
- An electrophysiological and morphological investigation of the projections of growth hormone-releasing peptide-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus. · retained source version 1:2019-07-12:current:c8ed2a7333778ee25893289027dbe314311e07f86bdbf08097c561d518d8a159 ↗Source checked November 16, 2026
- An epigenetic framework for understanding contextual influences on neural and socio-emotional development: Narrative review and case-study of the oxytocin receptor. · retained source version 1:2026-08-13:current:3e47920df091609d8234395493fd9596db3368ed0d5e55fe89325d23e89f7f67 ↗Source checked November 16, 2026
- Analytics of the therapeutic peptide aviptadil by sheathless CE-MS and comparison with nanoRP-HPLC-MS. · retained source version 1:2019-01-01:current:9c7954565528f5cd54d783227b3285784432497a7d4c4e44f4d6e004a90cc8b4 ↗Source checked November 16, 2026
- AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. · retained source version 1:2021-11-29:current:aeec6c87c0894277e9ef5b801f65b1dd415925072d23660268292870a2ca38d9 ↗Source checked November 16, 2026
- Anterior cingulate cortex, anterior insular cortex and altruistic behaviors; a hypothetical role for oxytocin. · retained source version 1:2026-09-03:current:60f074ba525c4e21d940d669720d48c729e8449b0bbbab054fa0280fa5805abb ↗Source checked November 16, 2026
- Anti-HIV agents. T-20 (enfurvirtide, Fuzeon). · retained source version 1:2018-12-01:current:cf32da3c6c8334461b05e5815641976973ee9a17d6b600956d3910ed1bc733e8 ↗Source checked November 16, 2026
- Anticipated pharmacological role of Aviptadil on COVID-19. · retained source version 1:2022-07-16:current:2a576d255bd90e5184469b212128a9903515107005dfa946141a7821ff4d2323 ↗Source checked November 16, 2026
- Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. · retained source version 1:2016-11-24:current:debd3ad5e4a6f53f184fc4373ccc38a4bfabd410f5a7c99806af50cfc75b5f37 ↗Source checked November 16, 2026
- Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. · retained source version 1:2020-11-16:current:b6841e2283efc507f2af7da1e32e82018c68b93d0aef64af4db30c20e4fbfd00 ↗Source checked November 16, 2026
- Antiviral properties of structural fragments of the peptide Selank. · retained source version 1:2026-10-16:current:8ffb138959a33d4e41a86da53fa13a876c3b81f7bca7f1c49356caacfb3707f3 ↗Source checked November 16, 2026
- Apremilast, albiglutide, and empagliflozin. · retained source version 1:2015-06-15:current:e0441a206b03fbeebb0f5909d150a3d64f0d398dcae63635621817b35b34d7a4 ↗Source checked November 16, 2026
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis. · retained source version 1:2018-05-25:current:e32881dcc16e5980e786773d722b98520e964b664c96603c96378c7f042def26 ↗Source checked November 16, 2026
- ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. · retained source version 1:2018-05-25:current:6ccef3c0cfb1a3feb594dac968dad647706a98b96e2e93ad17eb253839062898 ↗Source checked November 16, 2026
- Assessment of mitochondrial peptide humanin in women with polycystic ovary syndrome: serum and skeletal muscle profile. · retained source version 1:2026-11-09:current:57c8ce0c9ed196f7504565900c82304fe606a71e8e468e519b21a4cbd5b2d810 ↗Source checked November 16, 2026
- Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. · retained source version 1:2026-08-13:current:3dca2b03912c56d85d44d318a88dbd4a4a2560315f1925a4585084912e8abeb3 ↗Source checked November 16, 2026
- Aviptadil (Senatek). · retained source version 1:2019-01-01:current:8b956b7f3b1df037057a0d0554630ae2818c682c74ca77efd904a37ba38fe6ac ↗Source checked November 16, 2026
- Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage? · retained source version 1:2026-09-25:current:51285ccffe5cc5284044da4b58fc4fe80cd1b433d2a7b98f92192dbdeca71d29 ↗Source checked November 16, 2026
- Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis. · retained source version 1:2025-12-12:current:565bcb8cab84478a825d366b7da982de62c958d4d6c544f4375a1c04c31b7a71 ↗Source checked November 16, 2026
- Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma. · retained source version 1:2026-09-26:current:901673ab845dbde1dc67196cfca737df97d6f752e872955a5348eef9d0503bce ↗Source checked November 16, 2026
- Beyond lactation: Central oxytocin in maternal mental health and disease. · retained source version 1:2026-11-06:current:95f2bef52da4e770120dca33637e2175702872dac3ee7f1ef0cdb62855e712d9 ↗Source checked November 16, 2026
- Bioavailability of buserelin and gonadorelin in suspensions. · retained source version 1:2013-11-21:current:773a4734e3dcaef434abe6da6ad4d053837499a458d43971ad72e6736541d968 ↗Source checked November 16, 2026
- Biological assay of luteinizing hormone-releasing hormone (gonadorelin). · retained source version 1:2019-10-31:current:0124870f67b9cced2d15683aba090328566ba6a0c9a7daece9121b9574af8bae ↗Source checked November 16, 2026
- Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. · retained source version 1:2023-04-11:current:9a8aac78ae26c44796ed9d86c7d1a50bd5a741b765b813c42ad696a82b936d5e ↗Source checked November 16, 2026
- Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients. · retained source version 1:2025-02-28:current:db5d3057354ee7f6f83ed3482b6b2736492b6e0429ee35de867e49862b26187c ↗Source checked November 16, 2026
- Cardiac examination in children with Laron syndrome undergoing mecasermin therapy. · retained source version 1:2021-02-13:current:38a182b2c7cd8b036d18823704710106d0296f1c2581d13606ee1dc6af094e5f ↗Source checked November 16, 2026
- Cardioprotection by Thymosin Beta 4. · retained source version 1:2026-01-27:current:456c7034e7ad5db8ffec4376f681dbc87ebdf3a5abcb1b68251fa57383f86185 ↗Source checked November 16, 2026
- Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. · retained source version 1:2026-01-27:current:e38494a598b3d1806034fb75e9893fae274e3d588d9ef8ed9cfd9230202f623e ↗Source checked November 16, 2026
- Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study. · retained source version 1:2026-11-13:current:88a3f6f3b812375c4f71c62f26ad40fc1057ca83c817126d5a97660548fde8f6 ↗Source checked November 16, 2026
- Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management. · retained source version 1:2025-04-12:current:88f62ee9a3623872119619aae9c4e60c6bff8823f5d3290e07ef941feb3b28f1 ↗Source checked November 16, 2026
- Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. · retained source version 1:2022-01-10:current:239914252f2e0b78e00fd3b1d5b6dc6cc77385d5f4ca2ab146afda68b40b0a6d ↗Source checked November 16, 2026
- Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. · retained source version 1:2026-01-27:current:4c1643a302c0f0b15a5559eeb811fad050baeb1ffac5667ecf20270fa70b9bcb ↗Source checked November 16, 2026
- Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi. · retained source version 1:2025-01-30:current:95bddc1e47d276c079b4c87ef4b3181b1625a68cd150868b6f95297897f8faf6 ↗Source checked November 16, 2026
- Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone. · retained source version 1:2026-10-09:current:709434a097623c12f1f75ba308c5af0d70edc4c75c881f86db2d0efad972b51c ↗Source checked November 16, 2026
- Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date. · retained source version 1:2026-08-13:current:289aa023c00834affe07cc8eb8d20a123715d63f2eb799abc0bd59f1eb3ca2cf ↗Source checked November 16, 2026
- Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. · retained source version 1:2026-10-10:current:b9b26e5cf88037e0817a9ac9c373210e70dff6e8ff1e296c480f42d49622954b ↗Source checked November 16, 2026
- Cerebrolysin for acute ischaemic stroke. · retained source version 1:2025-05-30:current:656afa5dd207d5f55d9d28ec4d55a5d22c0a47eb00aa479a78a826f19f00a838 ↗Source checked November 16, 2026
- Cerebrolysin for acute ischaemic stroke. · retained source version 1:2025-06-23:current:bb842343df5eb308a6202233ba12258d1f3e0f673c6a367111a81ef71a6cefd3 ↗Source checked November 16, 2026
- Cerebrolysin for acute ischaemic stroke. · retained source version 1:2025-06-26:current:0db14acbb5e1828f84cdc8123a150cc36ab00436a0b4f75fdd31bcfeff5f55fb ↗Source checked November 16, 2026
- Cerebrolysin for acute ischaemic stroke. · retained source version 1:2025-06-26:current:50b60acd871a6ecd58e50f7b643c4bbb8a6850bf232458bc4c4013ee30834760 ↗Source checked November 16, 2026
- Cerebrolysin for acute ischaemic stroke. · retained source version 1:2025-06-26:current:598a607673200cc69e92a153f30d25cfcf63683500645f34c2794cee10872f90 ↗Source checked November 16, 2026
- Cerebrolysin for acute ischaemic stroke. · retained source version 1:2025-07-11:current:4a36ccfb63468a2f207b820a1547ddbca60a2fb12e18a65a26baf70130ec2975 ↗Source checked November 16, 2026
- Cerebrolysin for vascular dementia. · retained source version 1:2024-09-02:current:14b0b9e2e07dd954e82ecda50f00546a10b8d60d29b1cd6fe7a41175242baa8c ↗Source checked November 16, 2026
- Cerebrolysin for vascular dementia. · retained source version 1:2025-07-11:current:8dad474edf89786e05d2e17b23a89d4a0ad8312459b534c950924e23c00eba0a ↗Source checked November 16, 2026
- Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. · retained source version 1:2026-09-21:current:7f20db4b12624da6e0f102182e8bc98ae63f5689a9f08cfafa880b6bc85f272e ↗Source checked November 16, 2026
- Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. · retained source version 1:2023-03-31:current:07281eed3cf50d81946dcac5e12ba4e8ba3e8be6fabf6f69a1c2ce109c887be0 ↗Source checked November 16, 2026
- Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. · retained source version 1:2021-10-28:current:181a186439402ed5a6742359c71b9e2ad5ad04e9c9f33e44ed3b3c374383616c ↗Source checked November 16, 2026
- Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study. · retained source version 1:2022-03-31:current:9df88f0d16cc91c8bacb3577363c46af907ed1783c757b3aa8e1f07f4ab6fe9f ↗Source checked November 16, 2026
- Cerebrolysin: a multi-target drug for recovery after stroke. · retained source version 1:2019-05-09:current:29348255bef59f7e98aec281720fdbbd75d1901a65c31d4d6a8d8a480bf77202 ↗Source checked November 16, 2026
- Cerebrolysin: a review of its use in dementia. · retained source version 1:2026-10-11:current:b8e73e6e21897694129ef6c3efc0ce7d1eb2098135d9fd3f2d4eaa11adb977e1 ↗Source checked November 16, 2026
- Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy. · retained source version 1:2026-01-10:current:48c999a493d2d92ccff66c2aeeb3443c1d3d489a61e34c08f84077f51a0c506d ↗Source checked November 16, 2026
- Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products. · retained source version 1:2019-12-10:current:e161e816e28d5c03f15cc727c4e29988bf0181f2e06e660391952648ec3bd134 ↗Source checked November 16, 2026
- Characterization of a rabbit antihuman mechano growth factor (MGF) polyclonal antibody against the last 24 amino acids of the E domain. · retained source version 1:2008-04-09:current:b729273322858755fca79fe2872c8ae54ef91757de1f51ffeb5f41404a0d4f1a ↗Source checked November 16, 2026
- Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. · retained source version 1:2019-07-18:current:e26df264b06289a7b1ff243935e36ca6da102e7200c594220a17c4e29944a86e ↗Source checked November 16, 2026
- Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. · retained source version 1:2006-11-15:current:d9fcb443dcd103f0208565862d7364956136fd39e76f80734d7d8da178fa8a39 ↗Source checked November 16, 2026
- Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren. · retained source version 1:2022-01-31:current:f12b83f64da5e2a95a794ac6ceb51beb07308d2bc9c2a6c8615cfae800e9ff68 ↗Source checked November 16, 2026
- Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist. · retained source version 1:2019-07-10:current:b4396c273f604fa65e817dd4c5b857f2a58f0e6d111b45d15611b1ca938f053c ↗Source checked November 16, 2026
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. · retained source version 1:2026-08-13:current:878ddef4031548e4f3813bc00d2f9a531b6b17fe43c8b3a0026c7ea88cd86850 ↗Source checked November 16, 2026
- Children with autistic spectrum disorders. II: parents are unable to distinguish secretin from placebo under double-blind conditions. · retained source version 1:2019-05-01:current:2e3bf184921d0f19fc27953ea732447ef3276d4d569691beea6daa52610609c6 ↗Source checked November 16, 2026
- Clinical experience treating endometriosis with nafarelin. · retained source version 1:2013-11-21:current:a6f5fa0545d094860ca7524fec4f247795bd87f63420ad3daa4780bb6b72154f ↗Source checked November 16, 2026
- Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. · retained source version 1:2026-10-10:current:a4a6a972ef831a9a328f0e16e824ca95264260bcad31cbc05161b5cd984100a5 ↗Source checked November 16, 2026
- Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case. · retained source version 1:2026-11-09:current:2afbae074adcf84438d6321e4b44e4c10f0eb215bdf1255136a9c61680fa3bdf ↗Source checked November 16, 2026
- Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. · retained source version 1:2013-11-21:current:1cf7f28c2bd113f737351c46f75d3bd8d031243e78b099ba5ad59395cc03df4f ↗Source checked November 16, 2026
- Combination treatment of nocturnal enuresis with desmopressin and indomethacin. · retained source version 1:2018-11-13:current:18fa92250ece0018f3a416880e91403894f1727ef455f25d8e503b2964a77b33 ↗Source checked November 16, 2026
- Combined growth hormone-releasing hormone and growth hormone-releasing peptide-6 test for the evaluation of growth hormone secretion in children with growth hormone deficiency and growth hormone neurosecretory dysfunction. · retained source version 1:2018-12-01:current:8fd050755850e12d10671a86823736a5cd571a8f0b4f0f85598b25fe4d66bece ↗Source checked November 16, 2026
- Combined nuclear magnetic resonance spectroscopy and molecular dynamics study of growth hormone releasing hexapeptide GHRP-6 and a cyclic analogue. · retained source version 1:2016-11-25:current:c38670aa5d6a8acda3125283df55315d051def19c904e864c2481ae2879f1d0d ↗Source checked November 16, 2026
- Commentary: larazotide acetate - an exciting new development for coeliac patients? · retained source version 1:2018-12-02:current:064af4bba5db73da94a54b459fb12f0686fd6f6d939cfa42474a2ea3213ea29c ↗Source checked November 16, 2026
- Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply. · retained source version 1:2018-12-02:current:38df01b65a5e9d5c13b4033b2078b9dc69a1eab54cd0af8082c74bf25b481e5f ↗Source checked November 16, 2026
- Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience. · retained source version 1:2026-07-11:current:1a6503110c10dd65b42f3d8f7ed3cab407b94dd5169fec82ecbb7fcffd0ce85c ↗Source checked November 16, 2026
- Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis. · retained source version 1:2023-09-13:current:6c558221f541d026bee079a05440a1a9aa2d400916ebfe8fc02f76205ecbe80c ↗Source checked November 16, 2026
- Comparison of biologic porcine secretin, synthetic porcine secretin, and synthetic human secretin in pancreatic function testing. · retained source version 1:2019-09-06:current:0378f0186b9311ffadb1da17852b80aec130d5c2f7a0472e1333ba00771124b8 ↗Source checked November 16, 2026
- Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate. · retained source version 1:2020-06-11:current:9aab94d9010d289fd4f1cbebf97973daa34c06062824c0f15edee2507a18d9b7 ↗Source checked November 16, 2026
- Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis. · retained source version 1:2025-04-07:current:20a260df79bc1cbe3b5027f79eb3e37c6ce34592cae9cea90e89b8920110d3d0 ↗Source checked November 16, 2026
- Comparison of the pharmacology of nafarelin and danazol. · retained source version 1:2019-06-15:current:874a031cb93e333ac8584fc871681534062f5d7cf6dd90d2f051e3fc41befb78 ↗Source checked November 16, 2026
- Consequences of splice variation on Secretin family G protein-coupled receptor function. · retained source version 1:2021-10-20:current:e2006e4ee99ce1fdc31823c7b870031bdeb2343d3bde6df9d49f5e78e25901ef ↗Source checked November 16, 2026
- Context-dependent oxytocin receptor signaling: from molecular architecture to transcript-level receptor engineering. · retained source version 1:2026-10-24:current:d8cde4e7459007c8f4f43244aff46eb172fc458b72c0b53950036e3b2b642912 ↗Source checked November 16, 2026
- Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. · retained source version 1:2021-10-20:current:7dbcf0e2e522bc2c0d15a2f63fecbba504d75e38c3c73320992b75eddf2114a3 ↗Source checked November 16, 2026
- Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide. · retained source version 1:2010-11-18:current:83439f476d31a43f7253dd64ea6ab5b77a13ad6dc57b370f85d217419faed378 ↗Source checked November 16, 2026
- Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment. · retained source version 1:2019-12-10:current:035a6a76771bd978f6ad1dd96d2a4dc70af4a99582f96bdcd43696dc9fdff8a4 ↗Source checked November 16, 2026
- Corticotroph and adrenal responsiveness to hCRH, hexarelin and ACTH in young and elderly subjects. · retained source version 1:2018-11-30:current:413639a0b6fb98f6d69ec2201100672dbf5163b498066f9dd5bcfd8dc3693de3 ↗Source checked November 16, 2026
- Critical review and recommendations for nesiritide use in the emergency department. · retained source version 1:2013-11-21:current:bcd65f06569cb91e4ac4c67eaf34db87e40993dfed90d138221c3d389bf7c480 ↗Source checked November 16, 2026
- Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma. · retained source version 1:2025-09-06:current:35ed90fc6803dbf0ab02333a899744e05738178732f47ea83a55f8cfe33dcc65 ↗Source checked November 16, 2026
- Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms. · retained source version 1:2026-08-21:current:ef51a42ccd9ee53c363ba35d27e3a7a4024c00d41537f906307998c6868bea16 ↗Source checked November 16, 2026
- Current trends in the real-life use of dalbavancin: report of a study panel. · retained source version 1:2021-05-27:current:509b7a345363a70e990d39377ba7b7de31e00627cc532c10343e4a9a502420e6 ↗Source checked November 16, 2026
- D-Lys-3-GHRP-6 impairs memory consolidation and downregulates the hippocampal serotonin HT1A, HT7 receptors and glutamate GluA1 subunit of AMPA receptors. · retained source version 1:2021-06-21:current:0cf04dfaff7df1eb557c9e01da853f6ee12864a7ed0a81bd359cc18be2e66fad ↗Source checked November 16, 2026
- Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis. · retained source version 1:2024-03-08:current:dab3196b3da0c40f56c185226b8a7562f8f38d939dc25b2b2b6926db0687a247 ↗Source checked November 16, 2026
- Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review. · retained source version 1:2026-01-27:current:151ade346d25904bbe1d35e69cef6cb7cdb1707db73e4094469ddee22b6ad7a1 ↗Source checked November 16, 2026
- Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review. · retained source version 1:2024-05-18:current:ae51c30a0f8de646e7d329f982e472f1f6510a401f91c3c27b52c5dde7a898d6 ↗Source checked November 16, 2026
- Dalbavancin for the management of osteomyelitis: a major step forward? · retained source version 1:2021-06-22:current:f00ae6676e6dac033ef892dbc4b4be16dbd5706784c591776a3994469f64833e ↗Source checked November 16, 2026
- Dalbavancin for the treatment of bone and joint infections: A meta-analysis. · retained source version 1:2025-05-14:current:8f08810543f1c2154d52b64680b31ad959e56fb37e6b828d909932bfd8a31c51 ↗Source checked November 16, 2026
- Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. · retained source version 1:2021-07-10:current:0d115a587d452a8ac7550798a22d01e22cd3a342ed5c25b22a0bc8f21a2ed052 ↗Source checked November 16, 2026
- Dalbavancin in Bone and Joint Infections: A Systematic Review. · retained source version 1:2023-08-01:current:4c1a856a2fa10dc4765965c6b06083665aad2af304ed75cc95a6c2b7523cbda1 ↗Source checked November 16, 2026
- Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. · retained source version 1:2021-05-31:current:1ebcbab005e7d17ede720585fc25cfc5a099e51169f1da578675bdc8888e60cd ↗Source checked November 16, 2026
- Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. · retained source version 1:2021-07-01:current:cfcdf7efb706837da1119716685fc28b44641eb843d49e1ff36c95b566fa78a0 ↗Source checked November 16, 2026
- Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review. · retained source version 1:2022-09-15:current:22d242b1c45737ae583c4afd8a3462a06c4f7c6947ef5fabb19d5babd816c8cd ↗Source checked November 16, 2026
- Dalbavancin. · retained source version 1:2021-12-30:current:97c59327f44f302e2b31ebfbb49ca4c689373bfea67ea35c7ce46382e97707f3 ↗Source checked November 16, 2026
- Dasiglucagon Hydrochloride. · retained source version 1:2026-11-09:current:13af3370026a9336522d6d6dc224331c93278ab4ed1222e87e7a8c94b15ac3f6 ↗Source checked November 16, 2026
- Decoding the roles of pilotins and accessory proteins in secretin escort services. · retained source version 1:2012-02-02:current:de06eea50eb7cd231fdeef39efde4f524ce6099550494e4ccdac558d3a26b737 ↗Source checked November 16, 2026
- Decompensated heart failure: is there a role for the outpatient use of nesiritide? · retained source version 1:2019-11-09:current:dfe819d0657a1224d0122b02e4b00db4e89944f6408b849b78594c50883042b3 ↗Source checked November 16, 2026
- Degradation kinetics of gonadorelin in aqueous solution. · retained source version 1:2013-11-21:current:774cfcb61663939497358a0bc3d7802623b8f50863f8949222d99e22e986efcc ↗Source checked November 16, 2026
- Demonstration of equivalence of a generic glatiramer acetate (Glatopa™). · retained source version 1:2015-12-16:current:3b86c1deb4ec802cbed473356bf5d952940a57168b86fccd200e15efbfbef1ea ↗Source checked November 16, 2026
- Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity. · retained source version 1:2019-10-22:current:c3456996c16fd554dc8bc23e4a386ad0d59ece7fd71e296fe796c1b01cdeb43d ↗Source checked November 16, 2026
- Desensitization to mecasermin in an insulin-like growth factor 1-deficient patient. · retained source version 1:2015-05-29:current:4b8030f51ff0988406e5e7359f651f060c4864cfec2b4100bdea57391f23b2a2 ↗Source checked November 16, 2026
- Design of chondroitin sulfate-based polyelectrolyte nanoplexes: Formation of nanocarriers with chitosan and a case study of salmon calcitonin. · retained source version 1:2018-12-02:current:c0e608b42079d17828825e39971d43de40b12444d72392692ac975e931ef6bd5 ↗Source checked November 16, 2026
- Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria. · retained source version 1:2019-05-30:current:b37f0cd50acf41e8ac4bc89d46f8fe0a8ec258c4e438b26f19950677ea5b9609 ↗Source checked November 16, 2026
- Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial. · retained source version 1:2017-02-09:current:b9d4cd93718e7ab7696e6e0897d81352bf024b23ca1a7b65737e3d3148cbcb39 ↗Source checked November 16, 2026
- Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. · retained source version 1:2024-05-02:current:ae31a1bf7eb72257b21e09603cd5e622dd343218a70ed4162cc3ea334c7b56ec ↗Source checked November 16, 2026
- Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review. · retained source version 1:2023-09-01:current:135076512ed6341af4a502343710f94778f78661b1c3ab86d5b0a1849c3e9c52 ↗Source checked November 16, 2026
- Desmopressin for nocturnal enuresis in children. · retained source version 1:2026-09-24:current:35c7f8246664e6c9281a281334bf3928979027280901a1d08e46a7c4ae7e1bde ↗Source checked November 16, 2026
- Desmopressin for treating nocturia in men. · retained source version 1:2019-03-26:current:1bc79e101322512d8c6f9117488f4411efb832f623139dfd32666e7df9cb33bc ↗Source checked November 16, 2026
- Desmopressin for treating nocturia in men. · retained source version 1:2025-06-23:current:dd275c5244966166a0754507cf7943e07e02fafaddca620fd5e9f1fdc18d9510 ↗Source checked November 16, 2026
- Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis. · retained source version 1:2023-11-07:current:131931d6e8b7ed8aa2b5253b8dd5e6ab9c43c935bab04c9b7a7c357fe7361881 ↗Source checked November 16, 2026
- Desmopressin therapy in children and adults: pharmacological considerations and clinical implications. · retained source version 1:2026-10-11:current:c62435664204d9869ec639d0835bf0d0119cbc9b5d95139a4d7226a84c088927 ↗Source checked November 16, 2026
- Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines. · retained source version 1:2022-04-20:current:cce92b47eb18c4db29a4ec96e63540dc8da4f19a42e8bfdb8fa757a8db5c7751 ↗Source checked November 16, 2026
- Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis. · retained source version 1:2025-06-26:current:2784f398a08807bc0fa4faf78c60003952ac6e98011360945aa81e5a43cc637e ↗Source checked November 16, 2026
- Detection of His-tagged Long-R³-IGF-I in a black market product. · retained source version 1:2013-11-21:current:3433e4da4048989d47591e64f26a42e4434983f4a0a5ac3f766747c00a4798ad ↗Source checked November 16, 2026
- Detection of Mitochondrial-Derived Peptide Humanin in Semen and Reproductive Tract of Caprine Along With Its Relation to Seasonality. · retained source version 1:2026-01-27:current:2f9cb2deac9eb082f752687f31298d8b416eeb0f0f77b089eeb6563bba824ce0 ↗Source checked November 16, 2026
- Deterioration of renal bone disease in patients treated with salmon calcitonin. · retained source version 1:2019-08-13:current:e1d316c6d711cef1d5b325f68eb039af97ea5750891de264a6452cc596cb4749 ↗Source checked November 16, 2026
- Development and validation of a bioanalytical LC-MS method for the quantification of GHRP-6 in human plasma. · retained source version 1:2026-01-28:current:c75500974d3ac10b55bb6ab7800d8e8bba7537240e606c67493ade70fe4b7b64 ↗Source checked November 16, 2026
- Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. · retained source version 1:2019-12-10:current:8d1f70631133616796877c199150f7f7789d56e08dd1c580ee048d584101a9b1 ↗Source checked November 16, 2026
- Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma. · retained source version 1:2025-05-27:current:65cc5143fe7da8368ee98228cb06ef9e226278692af862b31d737555f95588e8 ↗Source checked November 16, 2026
- Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel. · retained source version 1:2023-07-05:current:1dd5ed51c40c6b28a075f63e025e9076801d7a846caccd3001fa8f05c85f6f12 ↗Source checked November 16, 2026
- Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan. · retained source version 1:2024-09-18:current:4232ab70a5c6d0a92e5e46707775f77236de96a15ae5533b5965ef98ecf5525e ↗Source checked November 16, 2026
- Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction. · retained source version 1:2026-10-30:current:62a63971814bb423fbc37e1b457f5a356652b2fccf219a3ee6390cdcbbab4d60 ↗Source checked November 16, 2026
- Diabetes exacerbates brain pathology following a focal blast brain injury: New role of a multimodal drug cerebrolysin and nanomedicine. · retained source version 1:2021-11-24:current:c21d6e48017eda87d7760368754d03bf66f8721aba4993d5843bd15109a9b170 ↗Source checked November 16, 2026
- Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. · retained source version 1:2022-04-08:current:6dea7a511c8a2b37cd1abe375b41b75bb8edfacd58b011405271d67e5748bb7c ↗Source checked November 16, 2026
- Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. · retained source version 1:2016-11-25:current:82b4095e326e305d81a0de52a69d808724117c77fc9002577a1a2b44d5c9b3f9 ↗Source checked November 16, 2026
- Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test. · retained source version 1:2019-09-06:current:97036b07ebb1d80261b7fface2e5568ddd99132e923baa6c5fc612c62c3334f7 ↗Source checked November 16, 2026
- Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis. · retained source version 1:2026-10-29:current:620564f0a8f7ad8eb591aa46475350866117e67efe85e37a4df1cacce2078af1 ↗Source checked November 16, 2026
- Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test. · retained source version 1:2022-03-18:current:5027642b080ff4dfbf8eddf07bb9a123c4bda9072ff2d0c4959ade492c260c08 ↗Source checked November 16, 2026
- Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria. · retained source version 1:2026-08-13:current:68a2c67159668ce369180a5849f56ba2067d4bf04f024790dce44134c0d58f4b ↗Source checked November 16, 2026
- Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy. · retained source version 1:2026-10-22:current:33f10dd31893e6f4da9e3bdd42077a84b0d371dfedf9d7e570841a62c1781650 ↗Source checked November 16, 2026
- Distribution and Functional Implication of Secretin in Multiple Brain Regions. · retained source version 1:2020-02-25:current:6a6ebd32b602029035a22ffc70d9263e69dc238c15c9d589dcdb7937ddfdd282 ↗Source checked November 16, 2026
- Does desensitization to hexarelin occur? · retained source version 1:2019-11-04:current:3e27d132cd53d02bf867bc3dde80e052ba386fe0b3f0844518105990dde75a2e ↗Source checked November 16, 2026
- Does salmon calcitonin cause cancer? A review and meta-analysis. · retained source version 1:2018-11-13:current:534500c5f4bf60bb916ed9566d59611a29515327d7f8f61b0a8e765d0f27f9ca ↗Source checked November 16, 2026
- Doing Great With DOTATATE: Update on GA-68 DOTATATE Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Evaluation of Sinonasal Tumors. · retained source version 1:2021-06-16:current:a122523861a2772cbcf64de4e74b63a2c1889761890c47caecb12bb428ece26d ↗Source checked November 16, 2026
- Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan. · retained source version 1:2026-08-23:current:3e0a1561d2d5d2e6c817d7ffa1f4b587dcd9908ea722df5a8c7ff2487aba1478 ↗Source checked November 16, 2026
- Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice. · retained source version 1:2026-10-28:current:5cdddb6bb6fa1df3efddbff980cdb39ac8aeefa9934de8c455164247516327d3 ↗Source checked November 16, 2026
- Early life adversity, oxytocin system alterations, and addiction vulnerability: a narrative review. · retained source version 1:2026-05-13:current:90831899df772afb71ee70bda54a7b39cd613bd9e144c224e902e4e670d6f213 ↗Source checked November 16, 2026
- Efficient electroporation of peptides into adherent cells: investigation of the role of mechano-growth factor in chondrocyte culture. · retained source version 1:2013-11-21:current:0721db6b51bba92d505449874925d36b1c321734f1129a89bb54b3fd39e03886 ↗Source checked November 16, 2026
- Efficient process development for high-level production, purification, formulation, and characterization of recombinant mecasermin in Escherichia coli. · retained source version 1:2021-09-29:current:6f46addb793dc5b4aca078c19694d197dfafcb11233c4718c6aa023ba4065049 ↗Source checked November 16, 2026
- Efinopegdutide: a step towards precision in MASH therapy? · retained source version 1:2026-11-09:current:930645f05b948e3cddc7b41337a36b325a8a5a8ab4a221f26bc92c280f2f5ea9 ↗Source checked November 16, 2026
- Electrospun thymosin Beta-4 loaded PLGA/PLA nanofiber/ microfiber hybrid yarns for tendon tissue engineering application. · retained source version 1:2026-01-27:current:815f49f2f0c392236021ca757fb92f5022ebd808c3f1390361d443d54ecf785b ↗Source checked November 16, 2026
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. · retained source version 1:2026-08-15:current:2fb96d76abf28060d09950cc955b7875b2b4d71deae7b1dc4830624139e7abf2 ↗Source checked November 16, 2026
- Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. · retained source version 1:2022-03-09:current:118804b5464b6e2db2763f48b067d3564992e84b7b6e331cc80cba757d981714 ↗Source checked November 16, 2026
- Endometrial Preparation Strategies for Frozen Embryo Transfer in Women with Adenomyosis: A Systematic Review of Hormone Replacement Therapy, Gonadotropin-Releasing Hormone Agonist, and Oxytocin Antagonists. · retained source version 1:2026-09-28:current:7544b7ff4bdb8de072bb96fae85d32789b95c56bb7698770cac127eb5a01cce5 ↗Source checked November 16, 2026
- Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate. · retained source version 1:2016-11-23:current:ec9be430d3942fb1ae7a08cd68cbc40f48a803ebc6d451419f3a761b8d65230a ↗Source checked November 16, 2026
- Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. · retained source version 1:2020-09-29:current:ba386bd461c6b1145810ba0439309eff04491ffc7728ed9a4b26bb5709f3ed06 ↗Source checked November 16, 2026
- Enfuvirtide (T-20): potentials and challenges. · retained source version 1:2018-12-01:current:a32c0e154a744abfb5e655468f6a13c6cc91a5ff9b868f0f856e33e9f68c3b67 ↗Source checked November 16, 2026
- Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering? · retained source version 1:2018-12-01:current:24797492415fa8f805a5a35acd3b3c3f3271d72a0fa3df976d4122a118567238 ↗Source checked November 16, 2026
- Enfuvirtide biosynthesis in thermostable chaperone-based fusion. · retained source version 1:2022-07-16:current:50ab0b147ee56137097cdee8d3f7611d1d9e18e0526a3c425ac5e1e2e5b30188 ↗Source checked November 16, 2026
- Enfuvirtide: antiretroviral class 4, drug 1. · retained source version 1:2018-11-30:current:5cc8f6b50ba1be0bb653349c22e56366b734d283def110aee6fb02269ce7f15a ↗Source checked November 16, 2026
- Enfuvirtide: from basic investigations to current clinical use. · retained source version 1:2018-12-01:current:6c63dfa7f5312e8913ca6d0225e34d13acc36cac18458869b8d432433aa987e8 ↗Source checked November 16, 2026
- Enfuvirtide. · retained source version 1:2019-09-16:current:c887a6d5f23e634fd90cec2d81928c8eade97ea3c9884244111d882bae08df3d ↗Source checked November 16, 2026
- Enfuvirtide. · retained source version 1:2019-11-08:current:d6b8bd1c4d4de3decb0a19706bfc5ceafbed9b41d16beb42391e8cb35cc9912c ↗Source checked November 16, 2026
- Enfuvirtide. · retained source version 1:2026-10-11:current:63d4effd0f7dbc2e3ca624106f0692b6f6e8c914d4b8e1257ac0537603edfd7e ↗Source checked November 16, 2026
- Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke. · retained source version 1:2016-11-25:current:e15f17649951ad3bbfb5cb408d61f87cdb0cf01bbc8a8e5df5e831cca581d141 ↗Source checked November 16, 2026
- Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. · retained source version 1:2022-03-30:current:ac4cdaa48f9a463ae913fd4bde20e2a959525703d4aff3c958925d56a222ad13 ↗Source checked November 16, 2026
- Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes. · retained source version 1:2019-07-22:current:29dfbf6bff2207009101e96167493ae4303e462a2d421eba09eb2016e7655101 ↗Source checked November 16, 2026
- Evaluation of pituitary GH reserve with GHRP-6. · retained source version 1:2016-11-23:current:0071a051bf878ca0eee062b596a003ef8703c4170b1e7f79d4668af209e52597 ↗Source checked November 16, 2026
- Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®. · retained source version 1:2023-11-10:current:4e472b683c99457b9750aabbd30daee401ead3b5a5d92c8cab27cdb73d73868f ↗Source checked November 16, 2026
- Evaluation of the reproducibility of the GHRH plus GHRP-6 test of growth hormone reserve in adults. · retained source version 1:2019-12-10:current:a913a18efee8cbd3898d67aa17196f9839e38513ac6439359a57fae0d427ea6e ↗Source checked November 16, 2026
- Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. · retained source version 1:2018-11-30:current:722c052626278458f6af870f6a3b3414827c8bccdc5ba6fad4de20f35b250d0a ↗Source checked November 16, 2026
- Examination of alternate codon bias solutions for expression and purification of recombinant mechano-growth factor in Escherichia coli. · retained source version 1:2015-10-20:current:1483cf6dba42358cc1d370c1b1b351e896d9982f81b0aef5c8e8fc6e07835040 ↗Source checked November 16, 2026
- Experience in the use of nafarelin for treatment of benign breast disease. · retained source version 1:2013-11-21:current:f19f3fbcbdf5269a60b7a9e69b229fddec90760c27dec9916bec6a2cfd2a19b2 ↗Source checked November 16, 2026
- Experience with thymopentin in the treatment of periarthritis humeroscapularis, tendinitis, and gonarthrosis by local infiltration. · retained source version 1:2013-11-21:current:8d1ac3b78c5ca73ca69ba232a5a6fde8f18afeb97e20fb1084a8e57484e1409e ↗Source checked November 16, 2026
- Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial. · retained source version 1:2026-09-02:current:edf436b5b2a7a95e758e93ebedd17071036bdc1df73c58e72f50fb0fc2c837c1 ↗Source checked November 16, 2026
- Expression and subcellular localization of mechano-growth factor in osteoblasts under mechanical stretch. · retained source version 1:2016-10-20:current:7be849e8ed87c95d6f339bcb6557be8e718830c9ec9b2df40fa47146144b3743 ↗Source checked November 16, 2026
- Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. · retained source version 1:2018-12-17:current:c0512bacfa3997242787997946759462773d6324dd424014b5d0c4757a78db6f ↗Source checked November 16, 2026
- Expression of thymosin beta-4 in human periodontal ligament cells and mouse periodontal tissue and its role in osteoblastic/cementoblastic differentiation. · retained source version 1:2026-01-27:current:faca744085441c4ba53d9084466423d3ab9d2c2df2ca7a115ba05763fb851bc4 ↗Source checked November 16, 2026
- Extending the time window of mammalian heart regeneration by thymosin beta 4. · retained source version 1:2026-01-28:current:4f4947f4e2567a7c9c5bacdbc5d7eed9ecb7dc67e598e1e72521daeae5494d7f ↗Source checked November 16, 2026
- FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto. · retained source version 1:2026-09-16:current:073ef6cbbdb55cda9001b7136040ec6850baf34a147ea665958117e06017aa3d ↗Source checked November 16, 2026
- Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. · retained source version 1:2026-01-27:current:eeff640dab5554ea936e374173c271c7c9fdc01e16e254bac62461bae564fcf1 ↗Source checked November 16, 2026
- Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. · retained source version 1:2024-11-07:current:c4a7896494bf9a2ac033103564279f7d4ed2a69dfe876b43876b53dd17a7533c ↗Source checked November 16, 2026
- First metreleptin treatment for generalized lipodystrophy in Turkey. · retained source version 1:2026-01-27:current:8aa206d36eab69da6bcd4579ed2a3e4bca5ff522621b0cc6938a8d13fae5f687 ↗Source checked November 16, 2026
- Focus on the splicing of secretin GPCRs transmembrane-domain 7. · retained source version 1:2009-09-14:current:ff0e94b498e87683c581684fe51db98eb747af22d3c4903818f865682ed72dea ↗Source checked November 16, 2026
- Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental development and preeclampsia. · retained source version 1:2022-10-04:current:ce1e7de940de72cbe363a3a5f58d8c76a0971764999c03c858bec66a88a2f69e ↗Source checked November 16, 2026
- Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity. · retained source version 1:2026-09-11:current:7ff3ccf348a2b50b471fc067d9cf13db2e619581d7ad35deb09622b2f8dcec9a ↗Source checked November 16, 2026
- Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury. · retained source version 1:2022-03-29:current:f39e7c25807a73bb3647590b97bc7431de26f98288d632a02b8c759467e3958d ↗Source checked November 16, 2026
- GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. · retained source version 1:2026-07-21:current:fbfe72ce76e703fef1f65c8bf824e467b6bc05bd6fc988dcf1775ea45a2093cd ↗Source checked November 16, 2026
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. · retained source version 1:2020-09-29:current:e029b9f062ad8266dec7d69cfdf2d68fa4e5d1eb93aa8da86d5fb9a249b6a2b1 ↗Source checked November 16, 2026
- GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. · retained source version 1:2019-12-10:current:f6939c668a24d1a927ddd1f7859235de431ae953f5e4dd6cf2fce4a494633241 ↗Source checked November 16, 2026
- GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation. · retained source version 1:2026-11-01:current:f8194e4b297648848c4953deacf3475c4e5920a6c2a18901012319bdc0b452d4 ↗Source checked November 16, 2026
- Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair. · retained source version 1:2026-05-21:current:f1272ae1ef05e177ce7b7592fb14a1af40c6a8d9480e9da48cc6769f477aeb9d ↗Source checked November 16, 2026
- Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. · retained source version 1:2015-11-19:current:42394739cdea8f619ff5a7e42727b8750c3e1e19c2297df5619e9f528576a057 ↗Source checked November 16, 2026
- Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. · retained source version 1:2025-06-23:current:ee0d5b93cce41ee7209b65ba7b4348433bd994785a9f89949c33b30b8ba1d055 ↗Source checked November 16, 2026
- Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? · retained source version 1:2024-05-05:current:99c26f644b4a0b7a098f020e97abab6c0d60a443eac4ab7bc5f8291c8072cdfa ↗Source checked November 16, 2026
- Glatiramer acetate: A complex drug beyond biologics. · retained source version 1:2019-08-15:current:99eac34cd41e25faa059d05a6381d377e0452016d0fb3f3bdbf18c0f971f3412 ↗Source checked November 16, 2026
- Glatiramer Acetate: from Bench to Bed and Back. · retained source version 1:2019-04-01:current:1314fb9d1f5256072bb1428dc1ddc1b3af0aa16a0a4bf95866034a43e17c53a3 ↗Source checked November 16, 2026
- Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A. · retained source version 1:2026-08-30:current:be0ac44ebeb754b461d4884953a111995fd1d900572c3d60dabd887e6a054cc0 ↗Source checked November 16, 2026
- Global trends of dalbavancin: A bibliometric analysis. · retained source version 1:2023-03-24:current:1f8b53d42c6ecfb1d1599157f0a8731f17c89355a68735d4614ba8e93dd9556a ↗Source checked November 16, 2026
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. · retained source version 1:2025-07-03:current:3db59e0d44641ad8eaa5029f3754395bce7e2654d165ac66f318be75c2f9c38b ↗Source checked November 16, 2026
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. · retained source version 1:2025-07-03:current:9bd704fa04e5ac5b7fd5df4152a66fbcfcb6c5d0ba13474f1b8e68ebe1d518a2 ↗Source checked November 16, 2026
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply. · retained source version 1:2025-07-01:current:4a666e4fc1356751f3aebf7f2a6e59029b863800b0cb2310413d619e7fcab6ae ↗Source checked November 16, 2026
- Gonadorelin and erythropoiesis. · retained source version 1:2006-11-15:current:c9f7a56cb06396789a634b5e80c590d47dcd05be44345c6f6a4c707ebda29e4c ↗Source checked November 16, 2026
- Gonadorelin--synthetic LH-RH. · retained source version 1:2015-11-19:current:bfc9d27b7dea26eea65848984771e153f9bd31a28565e9640e4a6c2eb1af20af ↗Source checked November 16, 2026
- Growth hormone (GH) peaks versus areas under the curve in the diagnosis of adult GH deficiency: analysis of the variables provided by the GHRH + GHRP-6 test. · retained source version 1:2026-10-19:current:5a4afb693a189563988e6867ec9b8f92680895c217bad542f3f6076cf67f7cf3 ↗Source checked November 16, 2026
- Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. · retained source version 1:2016-11-23:current:8a18cf65b3e7563d9692a3e9e81a2a3e588dc83ef05fdc3cf0215fbda7681acc ↗Source checked November 16, 2026
- Growth hormone status during long-term hexarelin therapy. · retained source version 1:2012-11-15:current:496b4fae4d51d1d522b6b79616e2df4b4bcfee891bd749ef8aedfe63b098c464 ↗Source checked November 16, 2026
- Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study. · retained source version 1:2025-06-05:current:ec85659e66757b19a3a373aba15017703280dab0356437a1992a45482443a822 ↗Source checked November 16, 2026
- Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. · retained source version 1:2024-09-14:current:f9d9445b67daa2f97e3f331af000ff622ebb30d08a2d82fa490b692ebe31f3bf ↗Source checked November 16, 2026
- Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA. · retained source version 1:2026-10-10:current:0ae4e357a0df8c462b789a6116dfb30ac9f087295c60b13d347dc8e644527c09 ↗Source checked November 16, 2026
- Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. · retained source version 1:2024-11-06:current:5d5bd824878253a7a979f4a4d4dced8fecfb10d8f3dd2a833c9549e9840b3a4a ↗Source checked November 16, 2026
- Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver. · retained source version 1:2026-10-19:current:1be43273e2b0b80cd12f9f41f7ca5601559c0a0761e1ec45e8d01bc017030796 ↗Source checked November 16, 2026
- Hexarelin as a test of pituitary reserve in patients with pituitary disease. · retained source version 1:2019-08-13:current:b68892b98d11abd36bd26aae63d58687f19819a6da5be37136d0ea77220c717d ↗Source checked November 16, 2026
- Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. · retained source version 1:2026-10-12:current:93dde64fe596df826ba23a94c3904d43649f10e0819ae6d14c314371e885f97c ↗Source checked November 16, 2026
- Hexarelin Signaling to PPARgamma in Metabolic Diseases. · retained source version 1:2021-10-20:current:706c46ecd71e03e44c09ff1135dfcb4b993dc7a9558915ec01ce5b7e4d9abb95 ↗Source checked November 16, 2026
- Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. · retained source version 1:2021-02-11:current:958fd17f3ef7a475cf9b21777ece2a8d550f8015bcca853c30162b6cf5e6ee87 ↗Source checked November 16, 2026
- Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. · retained source version 1:2016-11-25:current:6d16b079a37eda0f05e75bfa273db1fb3b1223048baa78c98c5257aa07bbeae9 ↗Source checked November 16, 2026
- Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats. · retained source version 1:2012-11-15:current:249e824944c452c0c6f511c07617502ea181902f01fc4f1d54230294b66f1373 ↗Source checked November 16, 2026
- Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. · retained source version 1:2012-11-15:current:d54ae81873b7654eafdf1041266395cd668880e5e2f73bc1dbd550685122a7ee ↗Source checked November 16, 2026
- Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects. · retained source version 1:2022-03-09:current:4618174a899e114e20b9d79038c1f62df7e13b4b303da0f7096d2bea40363aba ↗Source checked November 16, 2026
- Hexarelin: a multi-receptor peptide. · retained source version 1:2021-10-20:current:3a3ef03742c95ed4bcb15091fdc4a4df663bf405b270aef3180c71334faefbaa ↗Source checked November 16, 2026
- Histrelin for central precocious puberty-a single surgeon experience. · retained source version 1:2026-01-28:current:644c4fbd7a06a556ccb1bdf9c6aeb643e4768a1bf50a76d6419329213ca0f919 ↗Source checked November 16, 2026
- Histrelin: in advanced prostate cancer. · retained source version 1:2021-10-20:current:8a41089731514dab539ad8962179088b8d996b2ae5606c92dec552b1afaea8ee ↗Source checked November 16, 2026
- Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty. · retained source version 1:2018-11-13:current:644d4fad787c122d84735ecc39d838e4fc967b8429188d1be1356d0e323003f0 ↗Source checked November 16, 2026
- How factors of the therapeutic alliance interact with oxytocin neurotransmission in psychotherapy. · retained source version 1:2025-12-31:current:20ba9ea2d96b810ecc788c39d58e1bdb91280afa192abd71e680a6d9d5983381 ↗Source checked November 16, 2026
- Humanin and age-related diseases: a new link? · retained source version 1:2018-11-13:current:3a85116a7dfd9ccbd46f4bbaaefa4335fbfc6d22c01a20db55d4235f29d981a2 ↗Source checked November 16, 2026
- Humanin and Alzheimer's disease: The beginning of a new field. · retained source version 1:2022-01-11:current:69a6d878692d66578c83dd66e1529d8178c7edf3af58496204516b99ecb1d99c ↗Source checked November 16, 2026
- Humanin and diabetes mellitus: A review of in vitro and in vivo studies. · retained source version 1:2022-04-19:current:e40ed2ef5059e3b107d2bbc1f3ebbd7cdfb09177e0897bf409046a2f48dad31c ↗Source checked November 16, 2026
- Humanin and Its Pathophysiological Roles in Aging: A Systematic Review. · retained source version 1:2024-09-17:current:d20aa3670f58ac0f1d59a09aec20d7abed25a2a45b11eaeb62cea75511013a03 ↗Source checked November 16, 2026
- Humanin and the receptors for humanin. · retained source version 1:2021-10-20:current:4b38c6d1afa6a44fb135fa1d4fe1920c0fc33c403d5afdb2b79bb93616a79240 ↗Source checked November 16, 2026
- Humanin as a Molecular Indicator of Semen Quality and Cryotolerance in Crossbred Cattle. · retained source version 1:2026-07-17:current:882c3fbd55f19864bdb6f7499dd623ac0a9f85767263112150bc02caa0a7e3fc ↗Source checked November 16, 2026
- Humanin as an evolutionarily tuned mitochondrial peptide: Insights from mammalian oxidative stress diversity. · retained source version 1:2026-07-11:current:17dfef6cc5ea586eb1fdfbb4aed35c790d0544f153c5018d29a07966bd91987d ↗Source checked November 16, 2026
- Humanin signal for Alzheimer's disease. · retained source version 1:2011-04-28:current:e0fe3c5f481ea29e33fc823eef860a19d7cded44a8877d805ef77a883dcfb4ad ↗Source checked November 16, 2026
- Humanin variants aggregate to produce different fibril morphologies. · retained source version 1:2026-02-24:current:4c1eb814cec990d9dcfc3fc0f913348fcf634ba1a92042db8ae06c1e721c7de9 ↗Source checked November 16, 2026
- Humanin; a defender against Alzheimer's disease? · retained source version 1:2019-11-11:current:46836b69abdc970eba6e1e970d57222fa8e3de00fc0db341e7a326c32022e118 ↗Source checked November 16, 2026
- Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases. · retained source version 1:2020-12-31:current:1c209aa74757bcd5add4200c0a3b061d4a5b64625ba1c341aa30137de8e1ab53 ↗Source checked November 16, 2026
- Humanin: a possible linkage between Alzheimer's disease and type 2 diabetes. · retained source version 1:2019-10-27:current:b189b3961fc49cf057abad7531ae0c3010dd06e0d906c2fa478a310418c5eb4e ↗Source checked November 16, 2026
- Humanin: after the discovery. · retained source version 1:2018-11-13:current:20e3105a1e357be91b2e36ed5f343dd998301733e99578277b51c918a0022708 ↗Source checked November 16, 2026
- Humanin: Functional Interfaces with IGF-I. · retained source version 1:2022-03-11:current:fcdf5d6d49cd777401202344682cb88a28c8530b89f2135dbd7216f6f2b99a38 ↗Source checked November 16, 2026
- Identification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist. · retained source version 1:2021-10-21:current:a6d66cb811135e2e4af14efcf9712c9496b2969af4433fb56b2e97c956b8ccc1 ↗Source checked November 16, 2026
- Identification of gonadorelin (LHRH) derivatives: comparison of reversed-phase high-performance liquid chromatography and micellar electrokinetic chromatography. · retained source version 1:2019-06-30:current:6bd4f0b1475d56d95998e32246887659d2bf6e77a7e44cd7a759a3317cf2d577 ↗Source checked November 16, 2026
- Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c₁ complex subunit 1 as serological diagnostic biomarkers of gastric cancer. · retained source version 1:2026-01-28:current:39e94902048a9b74759b9c06f0ea977d245d94315139b0656031ee65f399bc69 ↗Source checked November 16, 2026
- Immunological and virological study of enfuvirtide-treated HIV-positive patients. · retained source version 1:2019-07-18:current:ee8b6b94a60dbe77c7bae81cb85912b1201f126849b93b986e3f1d6fdc50ba22 ↗Source checked November 16, 2026
- Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. · retained source version 1:2026-05-18:current:903e5763f48e2432518c8509297eefe90916acdbac32ed312a436c9be642201e ↗Source checked November 16, 2026
- Immunomodulation with thymopentin in humans. · retained source version 1:2017-11-16:current:62e9e29c270e9bd40a936b7e65aff9546f10824d0f339928e2c665ec5786f9f6 ↗Source checked November 16, 2026
- Immunomodulation with thymopentin: in vitro studies. · retained source version 1:2019-10-29:current:5d5e38e19c909dc665ae2e9a454bde3ad31817d92f44d02971afeba25b1c6f4b ↗Source checked November 16, 2026
- Immunoreactivity for thymosin beta 4 and thymosin beta 10 in the adult rat oro-gastro-intestinal tract. · retained source version 1:2026-01-28:current:8c984451104fec56a2c19bda1a36da424b04200d19b29b248af8a3fb12195c24 ↗Source checked November 16, 2026
- Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. · retained source version 1:2026-10-12:current:a7a3ac935376e43afd8d14bb1f52b0f2807831a0c1dde58548e0e573bc8fba3d ↗Source checked November 16, 2026
- In vitro and in vivo degradation and mechanical properties of ZEK100 magnesium alloy coated with alginate, chitosan and mechano-growth factor. · retained source version 1:2018-12-02:current:d0fd6189af9394084015e637828bdb37738ced163f6e81c03695f7177181f8a9 ↗Source checked November 16, 2026
- In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres. · retained source version 1:2018-12-01:current:e3030832dee28f1549850a789fcd962840d2a4b810312504e64f2feca1fcc7a5 ↗Source checked November 16, 2026
- Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations. · retained source version 1:2025-02-04:current:429a1ae32de03b6c58b567cc2466c9b52ce184368fb4a05b364f5f6175c180ae ↗Source checked November 16, 2026
- Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. · retained source version 1:2026-11-01:current:1b19af9af51d5b05e743f7d0f9ee2dfaaedf16b072a5d403866141fa0aa75948 ↗Source checked November 16, 2026
- Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors. · retained source version 1:2026-02-25:current:162fe3d0e100744ea529bd401baa1c8c2074bd0269a5495add15ad2706dc1e22 ↗Source checked November 16, 2026
- Interaction of the growth hormone releasing peptide hexarelin with somatostatin. · retained source version 1:2019-08-13:current:52314b462f32815ffb87cdeb925a5c194c4d473ba512d29156b26dd67b09d973 ↗Source checked November 16, 2026
- Interaction of the growth hormone-releasing peptides ghrelin and growth hormone-releasing peptide-6 with the motilin receptor in the rabbit gastric antrum. · retained source version 1:2025-03-06:current:96f79db42f0e4ad9434bad840dd21328379e2f4c6c4e2a92ac88eb859e9f0d5d ↗Source checked November 16, 2026
- Interferon beta and glatiramer acetate therapy. · retained source version 1:2024-02-04:current:44f89c4436ac11461e0f62cdd182a1bf16e727beec3d5e9f236a4398b8066047 ↗Source checked November 16, 2026
- Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. · retained source version 1:2025-07-28:current:b26a79de013ab609bb938f68651c0a376900cd6ed6fa30f1eb4a03fa78ea52ae ↗Source checked November 16, 2026
- Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. · retained source version 1:2026-09-06:current:38b98d32077d7c2854a1953da17d18e0034f0699338c2786911b7ae335590105 ↗Source checked November 16, 2026
- Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research. · retained source version 1:2026-11-04:current:4f1cc17b37e087bf82f6f6bd0d9fcd1e8dc4028c935033b92688e95ee173ed59 ↗Source checked November 16, 2026
- Intermittent nesiritide therapy in outpatients with chronic heart failure. · retained source version 1:2019-02-22:current:b967a1fd42f8b701b4bdd08fb765b86f03a89dfd546d8d73e592ad6f132b190b ↗Source checked November 16, 2026
- Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. · retained source version 1:2018-12-17:current:a4ee255ff4edb77568c25847aa750f8d59f92614c50afa268809597270297dee ↗Source checked November 16, 2026
- Intrapulmonary drug delivery of salmon calcitonin. · retained source version 1:2019-08-31:current:1b7feedc0d3ab2247b40ecf94b2525a143b2b4e087589a27e3291f1c96e70c10 ↗Source checked November 16, 2026
- Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine. · retained source version 1:2026-09-03:current:9ce603371198019b7cdb9d063b030038b74341a1eb2d5121e8ce44ba2a3ffc47 ↗Source checked November 16, 2026
- Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin. · retained source version 1:2013-11-21:current:836742fbbcfbb4fb6143f7b70c596cadf52287661fadf7992b1b26ecdf7ef3da ↗Source checked November 16, 2026
- Iontophoresis of nafarelin across human skin in vitro. · retained source version 1:2019-08-18:current:01d2965e284339f7fea285a78161fa97a5fe4f7e65e3c625100222b4cd6bc266 ↗Source checked November 16, 2026
- Is there a use for nesiritide in pediatric patients? · retained source version 1:2007-11-15:current:e7c915b514b8e0cb49369ab6666a94f44502b2aa780c09db2e25c858314ace7a ↗Source checked November 16, 2026
- Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. · retained source version 1:2026-10-29:current:2a939a3286e3a5ee973e0307add4c75aff83149e6f34f04295c1f1f94632ad0a ↗Source checked November 16, 2026
- Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. · retained source version 1:2026-01-27:current:7b75017f7026100b9d19d460c0fa77e423e7b04a8794420529a99be8156f1905 ↗Source checked November 16, 2026
- Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study. · retained source version 1:2026-01-27:current:e0ee6ab9444a45b0f13e211ea69a5d2fb65c5c733ec22dd039244fc1bbc93a82 ↗Source checked November 16, 2026
- Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. · retained source version 1:2024-10-23:current:d556839a15af49afa5bb0c5caab8fe34f9c0d114967d8fb373ad2bc760384456 ↗Source checked November 16, 2026
- Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. · retained source version 1:2026-01-27:current:143b9cf85c4670f4bda82606cab58343ab5f687f2f68406c0e9e617fd6b7b1d0 ↗Source checked November 16, 2026
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. · retained source version 1:2026-09-27:current:82cc0c95365faaf7d3b6fcbf9472ff9b81a0b08f608d5af4aa29407ad76edeb3 ↗Source checked November 16, 2026
- Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. · retained source version 1:2026-08-13:current:3bde6d4d2e883118dc7189481cb0cbd29673a6c6d29a0f9995936d04a54c33c4 ↗Source checked November 16, 2026
- Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. · retained source version 1:2012-11-15:current:1376ca73b8ebb4b63c84039f349c0cb495ac91fadcb549d897c3a78e06701cb8 ↗Source checked November 16, 2026
- Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. · retained source version 1:2022-11-05:current:2c7c65778b709c379cfd88a269bdd435ff528ab1af166c4cb6f4e2e6ce30abea ↗Source checked November 16, 2026
- Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. · retained source version 1:2018-11-30:current:998b26b8e7a74c86af87a7e6e8a5c93c6cef6a1fbf1181522a5644ae67192aca ↗Source checked November 16, 2026
- Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. · retained source version 1:2018-12-02:current:eb1a84b3f01cd54ef5ccf1a8d35bda357b1077d90569b5d87035811382e1758c ↗Source checked November 16, 2026
- LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. · retained source version 1:2026-01-27:current:4bdf8b698c40396ed3ccb1d4e186d7e161a0102c4dc9e10a4e3a4e39377e3861 ↗Source checked November 16, 2026
- Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2. · retained source version 1:2025-09-14:current:c0dad1492d2bd6955cd26a680d36a198f73799b802ab9d1d9e9f2be08dd651f6 ↗Source checked November 16, 2026
- Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/Bone Study Group. · retained source version 1:2007-11-15:current:a618dba7f4f56c87d44108af0e2cbde78f2ab61863e2c224b9a230f7698bfb4a ↗Source checked November 16, 2026
- Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE. · retained source version 1:2023-05-01:current:e17df6fb84dca66021129e22ab56841e1c87c8fd77b9a27145c9b365002d05ca ↗Source checked November 16, 2026
- Lutetium Lu-177 Dotatate Flare Reaction. · retained source version 1:2022-04-20:current:a66ee0ceca5f47094427b919656a66ade7b16f16efa162862eb7627413d2cfbe ↗Source checked November 16, 2026
- MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer. · retained source version 1:2026-01-27:current:323ec31f383e34420c55363b3c378c3da22fed50d902e92b0985dfb534d461b5 ↗Source checked November 16, 2026
- Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. · retained source version 1:2026-11-03:current:e2c7150106c88920904f80cacdf70a9a2afef27c01cfe6787f0f347f4641e09d ↗Source checked November 16, 2026
- Management of viral infections with thymopentin. · retained source version 1:2013-11-21:current:e0c4cca9d3ba462ee2331da7a3e6836c43d65b21f184ab3ee6b7051ce3387431 ↗Source checked November 16, 2026
- Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. · retained source version 1:2021-10-21:current:27faf7add2b8299bf25a22613363d3fb51d5a8835786ac40bd4dafda128b647c ↗Source checked November 16, 2026
- Markers of the maternal oxytocin system and mother-infant bonding during the first postpartum year. · retained source version 1:2026-10-14:current:0f17f8ece999e9ff4d8c333d12f6d6f61ad050176a7acd8eb25a94e1862c8bd6 ↗Source checked November 16, 2026
- Mecasermin (recombinant human insulin-like growth factor I). · retained source version 1:2012-11-15:current:f4a1ecd4abb6cd2d34e495904470222798571edb0e5b3d01b9ecf6d6ea7bca94 ↗Source checked November 16, 2026
- Mecasermin for primary insulin-like growth factor-1 deficiency. · retained source version 1:2022-12-10:current:f4a9f302877d07e631433757f17363028677b6c9a21e5d0d62789c46fd2bc3ab ↗Source checked November 16, 2026
- Mecasermin for the treatment of Rett Syndrome: a systematic review. · retained source version 1:2026-11-05:current:3ad54ec93eafade66be50cb14b98f13df1c80c9762ddf7e2292526ffd1b8416e ↗Source checked November 16, 2026
- Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature. · retained source version 1:2019-01-24:current:33fe404f83475e7c61060dd57d873970412ee4dbde0d702a3080a78b7c6747a2 ↗Source checked November 16, 2026
- Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. · retained source version 1:2018-10-25:current:c7f7c7772e09a4b6abf45ff3522b4f75e6b5d21700a44944145999bcec8c1ba4 ↗Source checked November 16, 2026
- Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. · retained source version 1:2019-11-10:current:eb8cab9432b5bcee4fa662489cc858eddd921d87a96a489b284d2768a2657b2c ↗Source checked November 16, 2026
- Mecasermin rinfabate. · retained source version 1:2017-04-27:current:0687dcfa5df0a25e46871846e58062a7140db69aa229403d06a895a8e0d9461d ↗Source checked November 16, 2026
- Mecasermin Tercica. · retained source version 1:2007-11-15:current:6935007fceee11a7e9d1921c19b3c42859a545a095efd7d96e42ada7dcdf1362 ↗Source checked November 16, 2026
- Mecasermin. · retained source version 1:2022-03-31:current:9af075e9cb87a59b4dc681de52ada470d08feca429b64dd7e7df5526f80af906 ↗Source checked November 16, 2026
- Mechano-growth factor accelerates the proliferation and osteogenic differentiation of rabbit mesenchymal stem cells through the PI3K/AKT pathway. · retained source version 1:2019-01-08:current:5ff5cbbdf40d3da34e23eeee30b10ae1f6f2c1faa8f6ad239ff3ec3dbe85063b ↗Source checked November 16, 2026
- Mechano-growth Factor Expression in Colorectal Cancer Investigated With Fluorescent Gold Nanoparticles. · retained source version 1:2019-04-23:current:db6942b91227c3852765923fdceba3f234fdd9bf117ea8f3a62ab5ed1029a178 ↗Source checked November 16, 2026
- Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? · retained source version 1:2024-03-21:current:4f6d11d184d9cab84a393986191b94cfa6951054a87915f5dcf97a98bd0fd83c ↗Source checked November 16, 2026
- Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples. · retained source version 1:2017-11-16:current:5f09a642fa6f0ddb67a388aebff9b89aca8056a7595caac66d372381da801773 ↗Source checked November 16, 2026
- Metreleptin (Myalept): a leptin analog for generalized lipodystrophy. · retained source version 1:2017-11-16:current:e00746c16fcbe47a47b5ce0d068bab2e1a876fc8ee281e5046b5c667dfc524ec ↗Source checked November 16, 2026
- Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. · retained source version 1:2018-12-02:current:ff4e82d1a0dfd4bbb54a28e1e5a2169de871c5e22200e18fb5a60c7e1bb6acdb ↗Source checked November 16, 2026
- Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report. · retained source version 1:2021-08-26:current:ea193dcbaf0d309516fe08261c17b4af5632d7bd31c25f814c7758ce22437b6d ↗Source checked November 16, 2026
- Metreleptin In SHORT Syndrome With Uncontrolled Diabetes. · retained source version 1:2025-10-15:current:853ee76241eb30f6e5461ef60bb62a9148edbdea25dd71d3d6cf396f41fe095f ↗Source checked November 16, 2026
- Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report. · retained source version 1:2020-09-30:current:56409ac4e25dbaa8a605d7ce42cf44975700732a895ef344a4c7633e09e473b2 ↗Source checked November 16, 2026
- Metreleptin treatment of non-HIV lipodystrophy syndromes. · retained source version 1:2026-11-09:current:92dd720f374578896c5a9aaa9a7c88d8d096164edd4d2343f5cd2592b0bfbd3a ↗Source checked November 16, 2026
- Microencapsulation of mechano growth factor E peptide for sustained delivery and bioactivity maintenance. · retained source version 1:2014-05-27:current:0df3fa4ccdc14f20857fe6cd8a2eefeaabf57311a9dc423e125f2b4ebcc45814 ↗Source checked November 16, 2026
- Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. · retained source version 1:2021-10-20:current:242bac67dfabc48980c8cec984ee846ba8fe4fb6b4442ca4c9b833066111f758 ↗Source checked November 16, 2026
- Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases. · retained source version 1:2020-03-06:current:5aa89cade392a53c6c21214de85f87cf89da40d012ea9fafeb896f7c16572cb2 ↗Source checked November 16, 2026
- Mitochondrial-derived peptides and cytoprotection in acute respiratory distress syndrome: emerging therapeutic promise of humanin. · retained source version 1:2026-10-30:current:3f1e6c103ef816f5add493c0222ef7bab2bbb49a26cf68a624732806a08294a6 ↗Source checked November 16, 2026
- Mixed Intravascular and Extravascular Hemolysis Despite Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case of Switching to Pegcetacoplan. · retained source version 1:2026-11-03:current:f9453a6cce034dc6b5015494c99c937e5197aee5798feb19ed5565a06ca07b52 ↗Source checked November 16, 2026
- Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. · retained source version 1:2023-02-09:current:d46ad14e1aaacfd55a40724b7de9d92ab90604d2394f3262571e554d1ee73295 ↗Source checked November 16, 2026
- Molecular evolution of GPCRs: Secretin/secretin receptors. · retained source version 1:2018-12-02:current:b8547bd74423679dc8e401c22c704ea03931e0c9abe8fa008359668418eb44a3 ↗Source checked November 16, 2026
- Molecular Interactions of Zyesami with the SARS-CoV-2 nsp10/nsp16 Protein Complex. · retained source version 1:2026-01-27:current:269c4318fbf86d96114ec792e2702ed17142de2e5246f2cf81f2104d8c51627f ↗Source checked November 16, 2026
- Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. · retained source version 1:2026-09-11:current:a4405118e69c18fd7676a5adc73926cd72749635bf29479ba78bd1275d2c9098 ↗Source checked November 16, 2026
- Monoclonal antibodies to mechano-growth factor. · retained source version 1:2008-05-28:current:dfa1ccf1a56768b8e23e423b590b82ef7a38ace5029e032444de7776963f5699 ↗Source checked November 16, 2026
- Monosialoganglioside-GM1 triggers binding of the amyloid-protein salmon calcitonin to a Langmuir membrane model mimicking the occurrence of lipid-rafts. · retained source version 1:2020-09-30:current:5cef41553ec28c6f404e8ada4d32e10f4994b2cb57ed8d772313eb6342075cdc ↗Source checked November 16, 2026
- Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach. · retained source version 1:2022-05-01:current:feccc6605836efdf335711174228877beaf20ea7f66bbba7379b63551c0e3112 ↗Source checked November 16, 2026
- Motixafortide Acetate. · retained source version 1:2024-10-09:current:5a3c0499d430aadf43d28638c4786feaff5a89fcb1b76d5f1a31fdbc68143ba0 ↗Source checked November 16, 2026
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. · retained source version 1:2026-11-09:current:23b1564a2281305c6474597b6225a7f34d307ed0928a167a60175043c2bbef17 ↗Source checked November 16, 2026
- Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. · retained source version 1:2022-04-01:current:1ac8436395db8f72e98b5c1b8f1bcbacfddd4c9bed28fa7db6a74c5286345267 ↗Source checked November 16, 2026
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. · retained source version 1:2026-11-09:current:09de67b6a9967635985784a3306de9f6908e8de9ba91b253ccc9fbb373ed3264 ↗Source checked November 16, 2026
- Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function. · retained source version 1:2024-09-03:current:772387b77482eaefca5bf512a33f038114d074ddc88698d5a4320c725a695a0d ↗Source checked November 16, 2026
- MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. · retained source version 1:2025-06-03:current:abf9232455d8616e97784c0a8c9d2739f8d04b4b91331e8ea523c025aa93d30c ↗Source checked November 16, 2026
- MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. · retained source version 1:2018-11-13:current:bb82e109d1404824009a4817dd6a203e0919d6eb1c38a475f0f82a3fd0377703 ↗Source checked November 16, 2026
- Multiple functional involvement of thymosin beta-4 in tooth germ development. · retained source version 1:2026-01-28:current:7303604e08983493d029b586ca7c51c96cc2abd509d324aa44d2209dccccb41a ↗Source checked November 16, 2026
- Nafarelin in the management of endometriosis: quality of life assessment. · retained source version 1:2019-06-15:current:bc486be1dfadfffbc66783bf47111489a969e538e59b5e07a47022cc861316b6 ↗Source checked November 16, 2026
- Nafarelin in the treatment of pelvic pain caused by endometriosis. · retained source version 1:2019-06-15:current:b1d909a179223ae6888d695db91143eff01d8708d453d98e096157ad6cba15b6 ↗Source checked November 16, 2026
- Nafarelin versus danazol in the treatment of endometriosis. · retained source version 1:2019-06-15:current:2e9ab3d6bad92b9891ba2afa27981d85f0106f6d4309851881c91db1e48e0063 ↗Source checked November 16, 2026
- Nafarelin: a new medical therapy for endometriosis. · retained source version 1:2013-11-21:current:4f304961f3a37bdedab3c111d4d6d0669ad422cecbbfab2f4baa40b7a4a0aeac ↗Source checked November 16, 2026
- Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials. · retained source version 1:2015-06-25:current:fb5a46083405c058ab88f860e8552d8e0c42570ec335841a2d6b814f75e9c507 ↗Source checked November 16, 2026
- Nesiritide compared with milrinone for cardiac surgery. · retained source version 1:2013-11-21:current:2ed683263868e32ca0a891ae284ccb7f8da8311d8ab207c0996c2ac30e3869b7 ↗Source checked November 16, 2026
- Nesiritide following maze and mitral valve surgery. · retained source version 1:2025-04-28:current:19b3ba5c784f1ca5520a4bc05a0cd8ebeb2509dce442d4e4fecf8caad4fab431 ↗Source checked November 16, 2026
- Nesiritide for the treatment of congestive heart failure. · retained source version 1:2019-09-17:current:baf0ea20a05561470185705154ee538a96dddc8c5c41a4036bc22ef4d2ca937f ↗Source checked November 16, 2026
- Nesiritide for the treatment of decompensated heart failure. · retained source version 1:2007-11-15:current:3710a4dce99307df226be92cec8dd0b46addb1dd3a4f1a1dd517c42f00dd86c9 ↗Source checked November 16, 2026
- Nesiritide in acute decompensated heart failure: current status and future perspectives. · retained source version 1:2026-11-08:current:14b54a2667cdcb3ee4f799922c47915ae439db4b1a89b5eb7c4ac942b8bb61f8 ↗Source checked November 16, 2026
- Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis. · retained source version 1:2020-11-17:current:9e4a6634dcbe6b3d8d8abe9e7d7534a19ca5fa8b46e78ab732c77428adeea766 ↗Source checked November 16, 2026
- Nesiritide in the initial management of acute decompensated congestive heart failure. · retained source version 1:2008-10-06:current:8c3561e5f9ecea73d1bbdd95a5e96dc3d504845bc1557ae5a11e3aee25879244 ↗Source checked November 16, 2026
- Nesiritide: harmful or harmless? · retained source version 1:2007-11-15:current:25945ae375cee4bdf69c56e436b1170e038df1a666ec0c1eb051a002cfcce5e9 ↗Source checked November 16, 2026
- Nesiritide: past, present, and future. · retained source version 1:2007-11-15:current:42af16707c2ac2ad0c1af04854cd9d7050c45a031729fca3544909dc9e770012 ↗Source checked November 16, 2026
- Nesiritide: the clinical experience. · retained source version 1:2026-05-13:current:2117b2bb63027345973b5181ed917962be4a0c19f504818059139915aadd9695 ↗Source checked November 16, 2026
- Nesiritide: the latest drug for treating heart failure. · retained source version 1:2007-11-15:current:ab27dbd651665c825aeba5cfaa8682ee8be09e5a48212d0fde3bc6eef62ffeb1 ↗Source checked November 16, 2026
- Nesiritide: trials and tribulations. · retained source version 1:2013-11-21:current:4026ecaafb064f7d89d907e39fd98159f3034e1298bb463fde165e898335eb53 ↗Source checked November 16, 2026
- Network Topology and Interactomic Analysis Reveal the Regulatory Framework of the Humanin Protein Family (MTRNR2Lx Class). · retained source version 1:2026-08-13:current:2118757ce273b226f42cb68392cf3515a4d96598730eaa1beb131c33fd495205 ↗Source checked November 16, 2026
- Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. · retained source version 1:2021-10-21:current:c8b9f471581d79f34a2d018e397a07926351d6192dff63a4e4cb8e8939955d00 ↗Source checked November 16, 2026
- New advances in the treatment of generalized lipodystrophy: role of metreleptin. · retained source version 1:2024-03-23:current:0514676dda077b168d5ed9a63dc43224412af683303a799bcbae529f7f6f6d72 ↗Source checked November 16, 2026
- New proangiogenic activity on vascular endothelial cells for C-terminal mechano growth factor. · retained source version 1:2018-08-15:current:429507c645b52303f143591a9fac40ada9027920ec5ab61f3a76bdb70b6eef07 ↗Source checked November 16, 2026
- No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. · retained source version 1:2025-05-29:current:f940377c57e5e33136bfd38f18a66226ef7647d1c70c5282b3829111fedcf89a ↗Source checked November 16, 2026
- Noninvasive monitoring in a patient with SAH diagnosis treated with Cerebrolysin - case report and review of the literature. · retained source version 1:2023-08-21:current:671d124927463db450e7aa3a1d3df2255892e33170a4e7157fb69e52f3f29e7f ↗Source checked November 16, 2026
- Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. · retained source version 1:2025-01-27:current:f8f2b5718eb781c2317aefd2b4d7e8c7640fa8ec68e4d4bdedc2d4b768dde63b ↗Source checked November 16, 2026
- Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies. · retained source version 1:2026-09-28:current:831a576d689d07dfbb681a0a42f4b9b3104320f2a7922da8b288bd1367d086c3 ↗Source checked November 16, 2026
- On peginesatide and anemia treatment in CKD. · retained source version 1:2018-12-02:current:9a356f2cf3ffe632c0dffc4b7e9c2d640f978f55fde09223da624024a0011639 ↗Source checked November 16, 2026
- On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. · retained source version 1:2019-07-07:current:89cca5723c5ea5622d6446d64b717d9246fcfadd780b036af65c1a83730ef105 ↗Source checked November 16, 2026
- Opioids and the oxytocin system: Mechanistic interactions altering maternal neuroplasticity. · retained source version 1:2026-10-31:current:3500e400564591a7be039dd27dffd91da7589ebc2c1823459d062f1272095591 ↗Source checked November 16, 2026
- Orforglipron (Foundayo) for adults with obesity. · retained source version 1:2026-08-06:current:94a855d423a083ec87a13766380afdeebe125313cba78f0511d637c82e6ada01 ↗Source checked November 16, 2026
- Orforglipron Calcium. · retained source version 1:2026-07-21:current:7dbfb1366aab33686ed272e59f14a92445aff8390e2c8d361a41c4bf10b907e3 ↗Source checked November 16, 2026
- Orforglipron for Obstructive Sleep Apnea: Research Summary. · retained source version 1:2026-11-09:current:ba425677421c9e44b371fa974670d5e862809cc59f2d51789704674af9e633de ↗Source checked November 16, 2026
- Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment. · retained source version 1:2019-05-15:current:47f2257be1d8cf637cf9471d387a0eedebbef8fa9ccc0a33889323cd976902b9 ↗Source checked November 16, 2026
- Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence. · retained source version 1:2026-11-08:current:0f236e06992a619ce323bc6f56330c02c8b99a6a782588375e9b28ef025b04d4 ↗Source checked November 16, 2026
- Oxytocin and RAGE signaling at the intersection of social neurodevelopment and inflammation. · retained source version 1:2026-10-03:current:30145c821b91369c3f8965899179dabb4c5f944f735e88dc30d353cd63dd13f4 ↗Source checked November 16, 2026
- Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area. · retained source version 1:2026-11-12:current:ae7805db91a6db580754a0c9aa1fc046c957d4908c62d80bcc4532869590b69c ↗Source checked November 16, 2026
- Oxytocin beyond social bonding: Advancing neuromodulation, synaptic plasticity, and epigenetic precision in CNS disorders. · retained source version 1:2026-07-10:current:dca2943bc6ee73dc66c996f67ff04a97716444ada230bb4021dd09ce5dcb940f ↗Source checked November 16, 2026
- Oxytocin facilitates top-down and bottom-up attention to emotional faces in a general and temporal-dependent manner. · retained source version 1:2026-09-10:current:9406d05c8b7ad7f33ce3171ea46a9bf89816469da0b01cb0e9bbf902578a31bb ↗Source checked November 16, 2026
- Oxytocin for chronic pain and acupuncture analgesia. · retained source version 1:2026-07-07:current:ae34dd0acf50e46465ef50d6104f0d2f9eda5f28510d010199f64b7d864b99d2 ↗Source checked November 16, 2026
- Oxytocin in chronic pain: From analgesic to biopsychosocial adjuvant - An opinion paper. · retained source version 1:2026-11-03:current:d9d852776fc78829ce2d5f3aaa09d7cb8c84b83392e10cd3330a19b06d579469 ↗Source checked November 16, 2026
- Oxytocin, sex hormones and brain activity in facial expression processing: A sex-based systematic review. · retained source version 1:2026-11-05:current:8b8daee549bbeb67239ff84fc8ea0b39341cf79d4b2fbf9ef63491a33f0fc2d0 ↗Source checked November 16, 2026
- Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin. · retained source version 1:2012-11-15:current:1b5b835afa8799698421f0ca17ee39d89704e0645c3277bb58eddfec5b43a507 ↗Source checked November 16, 2026
- Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. · retained source version 1:2026-10-09:current:6a817979b50bb89081ffe037839f067ae54384fc5c1170093e9150aee26cd381 ↗Source checked November 16, 2026
- Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome. · retained source version 1:2026-10-14:current:f5608a0be290e78d9d8536f33363baab36cf27394a85aef4fb572f837a491b91 ↗Source checked November 16, 2026
- Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis. · retained source version 1:2026-08-28:current:fe6e27b378136a02133f0ff3dadc5fb9769610ccaea5b10b70bbe00d58885484 ↗Source checked November 16, 2026
- Pegcetacoplan for geographic atrophy: Bridging the "clinical relevance gap" through precision medicine. · retained source version 1:2026-11-10:current:bc9b0ed7e9c0235d800a6f9886c8d2beda221641379cda9333f91776195d1789 ↗Source checked November 16, 2026
- Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. · retained source version 1:2023-07-18:current:014f7a1c5acf6e63e59c7261bd20f7a2ca89a4db3c50e579c6be6f712bcdedd9 ↗Source checked November 16, 2026
- Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN. · retained source version 1:2026-11-13:current:692fb936290af8e9d3d03db369a047edaf19c0e6daf93d79cadeeb83737a9857 ↗Source checked November 16, 2026
- Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background. · retained source version 1:2026-07-20:current:22571f6b7c8b8f39a8ae7b413b4e492a93c39d488bbe65a79373acec6b933eec ↗Source checked November 16, 2026
- Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months. · retained source version 1:2026-08-27:current:fee8c87d901b7c336a1561c9fe939a8ae1e79664f38f35242d783078153cfcf5 ↗Source checked November 16, 2026
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. · retained source version 1:2025-07-15:current:b5c2fda2e88ac49c325c6c87fc0d70ac3fac3de95d48cbe741322116290363e3 ↗Source checked November 16, 2026
- Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. · retained source version 1:2026-08-26:current:d3ac622683d32abeca5fdea88cce2ad0c6bb01071a8385658686f2d4f383809b ↗Source checked November 16, 2026
- Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria. · retained source version 1:2026-09-01:current:46dc0ae7b9ca8131c1385916c79fe2c7be2652b96f103146d0fc3889a64ddb05 ↗Source checked November 16, 2026
- Peginesatide (Omontys) for anemia in chronic kidney failure. · retained source version 1:2026-01-28:current:06808a4e50abc77dc5f6a9f2bfb0f807871f339b71bcf1ea60a3abd030b8dd54 ↗Source checked November 16, 2026
- Peginesatide acetate, axitinib, and pertuzumab. · retained source version 1:2026-11-09:current:09dc80e204af3dbb6e448df862457bc8d9a5bd3bb8416c2af88908392edf01f6 ↗Source checked November 16, 2026
- Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star? · retained source version 1:2017-11-16:current:68d259f36fbad1dbedfe952f3eb38e6ec10a762bf12d12b150db61eecd5a4099 ↗Source checked November 16, 2026
- Peginesatide for anemia in chronic kidney disease. · retained source version 1:2018-12-02:current:9f0036084c2ebed3ee94ae6b7855622237c54acf5cb1edc03a2dd4a4e1727287 ↗Source checked November 16, 2026
- Peginesatide for anemia in chronic kidney disease. · retained source version 1:2018-12-02:current:c32f638a3c1ba4d25eb7e582ef4c9e4808296e72c1b4b72402fc9465575e3e28 ↗Source checked November 16, 2026
- Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. · retained source version 1:2026-05-18:current:fe38b7444462da53a614302cb4b6080c4225bb061a79fe7afe7dfd618c5bdc1b ↗Source checked November 16, 2026
- Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. · retained source version 1:2021-10-21:current:160405f6760aa9ecbe5668b2ad513bc7fa42d7c795c4e8e6c06edb10a8a5f63a ↗Source checked November 16, 2026
- Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. · retained source version 1:2018-11-13:current:abd70eff690e4ed3dbb951a0c9650ffe097ffaf08cbca2a24f48c9f781954de0 ↗Source checked November 16, 2026
- Peginesatide for the treatment of anemia in the nephrology setting. · retained source version 1:2018-12-01:current:bcb406c7320bfa3ca9da5a31bcdcd323f819db32477d1200e6c57a8ec901124c ↗Source checked November 16, 2026
- Peginesatide in patients with anemia undergoing hemodialysis. · retained source version 1:2026-05-18:current:0e7025afeb2646063f31f2a358196d9c8166a036c1a3a6c64927a89ebd31a747 ↗Source checked November 16, 2026
- Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis. · retained source version 1:2021-10-21:current:d3f15ad296f09277c682397fd71a5d47e9248b50149ef344fe5ec5907a80fe55 ↗Source checked November 16, 2026
- Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. · retained source version 1:2026-11-01:current:9e68429a4e2f7965d3767e6743f4b266a3794f8bce3aa764c83f997d33483b06 ↗Source checked November 16, 2026
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. · retained source version 1:2019-01-07:current:4769fdbd4066ec100c50053ffa5c1a521dee21cebaa0963b45a72c157d33578e ↗Source checked November 16, 2026
- Peptiligase, an enzyme for efficient chemo-enzymatic synthesis of aviptadil. · retained source version 1:2023-11-27:current:d5b4165a7e2346f744644c6eb1f42169a03f6e99a730a6bb63ff23680c0d4d37 ↗Source checked November 16, 2026
- Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting. · retained source version 1:2026-11-09:current:6d35707cd3523bf75d1f1a8a9b5ded6818c5455d13c452ce9619983603265b06 ↗Source checked November 16, 2026
- Perioperative Desmopressin for Patients Undergoing Otolaryngologic Procedures: A Systematic Review. · retained source version 1:2020-01-27:current:1a4a7f3f33cda4c91827e6fd1894b34168234d8308ef0347d77a7c9744f11f93 ↗Source checked November 16, 2026
- Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum. · retained source version 1:2019-08-18:current:92d3c8041a3ed0f25aa02b02eaff0d7db8e6240a2e6af99e0ed25a18a26354ef ↗Source checked November 16, 2026
- Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. · retained source version 1:2019-09-17:current:427eab852e05829937520f836f7c1b4c5e8a799b5d8c0c245def63b7cd4257e7 ↗Source checked November 16, 2026
- Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. · retained source version 1:2026-11-09:current:7e79a17dba975a39311b82eb639465e6b053d44d8b0d0f29b1691d277bcb33aa ↗Source checked November 16, 2026
- Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. · retained source version 1:2018-02-22:current:0e49fbb60f1fe6c334a527b610a23850a705b97ccda06aa2866fbcd568293072 ↗Source checked November 16, 2026
- Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. · retained source version 1:2026-09-24:current:2d3e27b983b4da42b1bb5e6433b4b923006049837442eef7653bd693ea173fe4 ↗Source checked November 16, 2026
- Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. · retained source version 1:2018-12-01:current:0ec3b0024fad5a83842ff9926baebb784e65d0d22b9d91e6b00a2bcc9e40fd36 ↗Source checked November 16, 2026
- Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. · retained source version 1:2018-05-15:current:9a3f212ecc28149b558a98994c0bfda3cf224ba8587d26268a74bd9a4ec111d0 ↗Source checked November 16, 2026
- Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. · retained source version 1:2026-01-27:current:9a399cce3d3654a6c0b98f8f0d3d5f17dd484548dfd7cb3dc2e6bb3ad67c9bec ↗Source checked November 16, 2026
- Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. · retained source version 1:2021-09-20:current:61036108e9549b8c2164811e1d2237d9b123300bcffc4d2a23ceb61dd27290b9 ↗Source checked November 16, 2026
- Podocyte and tubular vacuolization in patients receiving pegcetacoplan. · retained source version 1:2026-10-16:current:81754f1888ef14a3ae8ae9040243b5b855a4747c31f850d710b949bed418c25a ↗Source checked November 16, 2026
- Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. · retained source version 1:2026-01-27:current:f5ec248a9735aa9ea93965d7f70ad7314de30d8b2401eecae55eb7aec626fd04 ↗Source checked November 16, 2026
- Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. · retained source version 1:2018-11-13:current:d2a8f008a394d0082b9a23b921fbfeedbf6b1ca7a2ae58d5b04ac9401ad2a830 ↗Source checked November 16, 2026
- Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. · retained source version 1:2026-01-27:current:b376aecb18397a324d83b10f02e93f1e2092506e0a949b9f9c308edc3afe6c13 ↗Source checked November 16, 2026
- Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes. · retained source version 1:2025-12-19:current:c4b41020606edfcd3c037cca0eb5c15476eb550109c5e1bd09d0e47050381652 ↗Source checked November 16, 2026
- Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. · retained source version 1:2021-12-03:current:52d9d43c70bd2b766ec115c5c8ab7f049a65235f640c0aca3b416327d5042334 ↗Source checked November 16, 2026
- Postprandial hyperglycemia corrected by IGF-I (Increlex®) in Laron syndrome. · retained source version 1:2016-05-19:current:d71624450ea8f7b2b9b2ea9d833c0f17292de76d4b4c3472a0a90fbfa5c16d93 ↗Source checked November 16, 2026
- Practical application of nonrandomized research to patient care: a case study of nesiritide. · retained source version 1:2019-12-10:current:9d35076dbe3d4779a2dc2172f659b3faeb175ab8eb7373ae7cce2aa110237318 ↗Source checked November 16, 2026
- Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study. · retained source version 1:2019-08-16:current:f8990b395f6cbdbd9499eca44b27582c24e011fdebcee07d50cb27379af35ee2 ↗Source checked November 16, 2026
- Preformulation studies of thymopentin: analytical method development, physicochemical properties, kinetic degradation investigations and formulation perspective. · retained source version 1:2022-06-22:current:0a0da855319e23855bfcfa9e78d15daa5415247c0d0bfd9c868188dfcb50fee3 ↗Source checked November 16, 2026
- Preparation and characterization of an electrospun colon-specific delivery system for salmon calcitonin. · retained source version 1:2022-07-16:current:4be8514f81cc4fe4b8550988020c6fc1f9bc01c095a0205810e45d4645416c38 ↗Source checked November 16, 2026
- Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review. · retained source version 1:2026-08-13:current:65478acaa4295544d0e14ff35a0f723e745e383ab50ae68c5ae5f333967fb9e8 ↗Source checked November 16, 2026
- Producing human mechano growth factor (MGF) in Escherichia coli. · retained source version 1:2026-11-09:current:8a02fcb25ab91f4326bd3736417b9287ea20602fe64459cbabd02fc19e8c102d ↗Source checked November 16, 2026
- Production and characterization of highly purified recombinant thymosin beta 4 in Escherichia coli. · retained source version 1:2026-01-28:current:6e31ba02d1af7f55222e0c54f80869cdf648f3802b3dbb0599195e46967ae100 ↗Source checked November 16, 2026
- Production of biologically active recombinant salmon calcitonin in Escherichia coli and fish cell line. · retained source version 1:2025-05-24:current:250aa59b8cbf7d2e327e388a4f04d5498d30f3043c15abb86d872430a158a762 ↗Source checked November 16, 2026
- Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. · retained source version 1:2022-03-10:current:b48363726a057de0577fc02e0c91ef1cf943198157d22b34a25ffdfcd8e1a5de ↗Source checked November 16, 2026
- Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. · retained source version 1:2019-07-24:current:a636b9eafc5fadaa7816df0223dc84e52ea6d46dd7722a061ecb50cdf09b6c41 ↗Source checked November 16, 2026
- Proteinase B disruption is required for high level production of human mechano-growth factor in Saccharomyces cerevisiae. · retained source version 1:2010-06-16:current:ba71d242c0997ed553ec52777ddc5b259ea9e1477c2771d0965d6199afb6533f ↗Source checked November 16, 2026
- Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation. · retained source version 1:2026-09-26:current:a5ba0aa13e40e90eb658e40621083b668672c25e1135b17f53e7fe99ec59ddba ↗Source checked November 16, 2026
- Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. · retained source version 1:2021-02-01:current:2a247f630cab5331a124bd7206e227951d5f98188e1c950d0766cfccffe7bfbc ↗Source checked November 16, 2026
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis. · retained source version 1:2026-05-18:current:9be46e239a22a1e6b39a8798d80c0a1bfe00e33a6ff907ba26443806b75aad76 ↗Source checked November 16, 2026
- Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. · retained source version 1:2018-11-13:current:a4161af40a15aae37d13e52ffe72ff9cd46bde719b577964a902d13fe0bb642f ↗Source checked November 16, 2026
- Reassessment of enfuvirtide's role in the management of HIV-1 infection. · retained source version 1:2019-09-17:current:6b1478ae9a31ac6208b999666bebf9e8fc4fbec308eed2d82bc88244f083ebb7 ↗Source checked November 16, 2026
- Recombinant production of mecasermin in E. coli expression system. · retained source version 1:2020-09-30:current:6ac59de38963f80c3a4540c278b395703f997de50ead6f8f2cf01703c6fa3b93 ↗Source checked November 16, 2026
- Reframing oxytocin as a behavioral flexibility hormone. · retained source version 1:2026-11-05:current:e444d28eac7951159926e9979ef432b19159eaa090537d779852ce4a9392ce1f ↗Source checked November 16, 2026
- Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin. · retained source version 1:2019-12-10:current:3fc9a468855dc148ce9cb38d6c05c33f983b97b78d8947499a2474902fa4399f ↗Source checked November 16, 2026
- Reproductive performance of goats treated with free gonadorelin or nanoconjugated gonadorelin at estrus. · retained source version 1:2021-01-06:current:95ef4f129b1418c62b4bff0bb18c8f905a9fc66beb0496440e8c55c7471d0557 ↗Source checked November 16, 2026
- Rewiring connection: The role of oxytocin in interactive media behavior. · retained source version 1:2026-11-05:current:9f4d366280899fa82816b564ca8d4a065ad6cbf15c459f68293b3cad22c30f32 ↗Source checked November 16, 2026
- Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial. · retained source version 1:2021-01-19:current:59230b03cf9d6fd27c617083224c724d76cb57f9809f863884d7c3c449e3d67a ↗Source checked November 16, 2026
- Role of Cerebrolysin in cervical spondylotic myelopathy patients: a prospective randomized study. · retained source version 1:2019-02-21:current:af996573a013f03835f697e4132267ee8d5833b63191738971a5116762c1ed8a ↗Source checked November 16, 2026
- Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. · retained source version 1:2022-10-15:current:f5411cf9fe22a137329575c5df72303eec7ec2b3c6252cd416f43f4c245bb1e7 ↗Source checked November 16, 2026
- Role of Desmopressin in the Critical Care Setting. · retained source version 1:2020-12-21:current:97fe4f03461f4cf75bbddd96fc02df607a88d896c21c123ee986760971869d89 ↗Source checked November 16, 2026
- Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats. · retained source version 1:2026-10-05:current:2f1d0fd2cd93a40a3f348b4f5940499b6ef5bcd136e0988054fb60227fad8ac7 ↗Source checked November 16, 2026
- Role of nafarelin in the management of endometriosis. · retained source version 1:2013-11-21:current:c152f50ea7e01d5c8ab23cc04c1c57bf3ccd9a451423b47e51fb6fdf2c6c9671 ↗Source checked November 16, 2026
- Role of Oxytocin in Obesity. · retained source version 1:2026-11-05:current:ef7bc1152f85bd5e55854817f1a1fa76f2e77ce8f03550f71442b345f2dc49b9 ↗Source checked November 16, 2026
- Role of thymosin beta 4 in hair growth. · retained source version 1:2026-01-27:current:4cd8897b0c0b6c000d88e98410d2f67fb1fa10d34e30168eca66a11686683e54 ↗Source checked November 16, 2026